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ABSTRACT
The complement system, consisting of a set of plasma and membrane-bound proteins,
serves as an essential part of the human immune defense. Its activation (through the
classical, lectin, and alternative pathways) tags microbes for destruction by phagocytic
cells or even leads to microbial lysis. In addition, anaphylatoxins generated during
complement activation can trigger a range of pro-inflammatory responses. This
antimicrobial action of the complement system can, however, be evaded by many
microbes. Pathogens have developed a number of complement-evasion strategies, one
of which is the recruitment of serum proteins called complement regulators. These
regulators protect host tissues against excessive complement-mediated damage and are
present in plasma in high concentrations. This, however, makes them an easy target for
pathogens. Acquisition of proteins such as factor H (FH) and C4b-binding protein
(C4bp) provides microbes with the means to inhibit complement activation on their
surfaces.
Yersinia enterocolitica is a Gram-negative enteropathogen that resists bactericidal
action in human serum. This bacterium causes gastroenteritis and as post-infection
sequelae reactive arthritis, myocarditis, erythema nodosum, and glomerulonephritis.
The aim of the present study was to characterize complement evasion strategies of Y.
enterocolitica and to identify bacterial surface factors associated with this
phenomenon.
This thesis reveals that the Y. enterocolitica serotype O:3 adhesins, YadA and Ail, are
the most crucial serum resistance factors (I). Although the lipopolysaccharide (LPS) of
this serotype was not found to participate in serum resistance, serotype O:9 LPS
strengthened YadA-mediated resistance (I, II). Differences in serum resistance
between different Y. enterocolitica serotypes can thus be expected.
Y. enterocolitica was found to bind FH, a fluid-phase inhibitor of the alternative
complement pathway (III). The receptors for FH on the Y. enterocolitica surface were
mapped to YadA and Ail (III). Ail was found to acquire FH only in the absence of the
LPS O-antigen (O-ag) and the outer core (OC), whereas YadA binds the regulators
also in the presence of LPS (III). In addition, YadA appears to bind to short consensus
repeats (SCRs) of the entire polypeptide chain of FH, whereas Ail targets SCRs 6 and
ABSTRACT
- 2 -
7 (III). Importantly, both YadA- and Ail-bound FH is fully functional and displays
cofactor activity for factor I (FI)-mediated cleavage of C3b (III). YadA is a lollipop-
shaped outer membrane protein that consists of a head, a neck, and a coiled-coil stalk
domain. FH targets multiple higher structural and discontinuous motifs of the YadA
stalk (IV).
Another complement regulator shown to be acquired by Y. enterocolitica is C4bp (V).
C4bp retains its function when bound to the bacterial surface, and YadA and Ail
function as C4bp receptors (V). Similar to FH binding, however, Ail acquires C4bp
only in the absence of the LPS O-ag and OC (V). C4bp binding to Ail was likely
hydrophobic, but that to YadA, ionic in nature (V).
Taken together, these data provide evidence that Y. enterocolitica recruits the
complement regulators FH and C4bp. Thus, Y. enterocolitica belongs to a constantly
growing group of pathogens utilizing the most widely disseminated mechanism of
complement evasion.
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1. REVIEW OF THE LITERATURE
1.1 Introduction
Human beings provide a home for a myriad of microbes. Many microbes produce
vitamins and nutrients, ferment food, break down toxic chemicals, and protect us from
pathogenic microbes which we encounter every day. The latter, however, often find
ways to cause infection, exploiting a wide range of strategies to penetrate physical
barriers such as skin or mucous membranes and to survive and persist in the host. The
first obstacle they must combat is the action of the non-specific innate immune system.
One of its essential arms is the complement system, the first line of defense activated
immediately upon pathogen entry. The importance of the complement system in host
defense against invading pathogens is reflected by increased susceptibility to microbial
infection of individuals deficient in certain complement components. Complement is
bactericidal against Gram-negative bacteria, it acts as an opsonin, and its cleavage
products contribute to induction of inflammation.
That pathogens adapt quickly to environmental changes makes them tenacious
opponents. They express surface factors to manipulate the host complement system
and avoid complement-mediated recognition and eradication. Studying microbial
factors conferring complement-resistance at molecular level may provide means for
their neutralization, and this could contribute to the prevention and treatment of
microbial infections.
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1.2 Serum bactericidal activity – discovery and overview of the complement
system
The complement story, as reviewed by Lachmann (Lachmann, 2006), began in the late
1880’s when von Fodor, Nuttall, and Buchner independently observed the bactericidal
activity of normal serum. Discovery of the complement was, however, carried out by
Bordet (1870-1961), who received the Nobel Prize in Medicine in 1919. In 1895
Bordet showed the lysis of Vibrio cholerae by a mixture of normal and heated immune
sera. Thereby he demonstrated the importance of both for bacterial lysis: the heat-
labile “activity” of serum (termed by Ehrlich complement), and the heat-stable
antibody. Six years later, together with Gengou, Bordet published the first and seminal
report on complement fixation, in which he described the ability of antigen-antibody
complexes to remove complement activity from serum. Complement was regarded as a
single substance until 1907 when Ehrlich and Brand fractionated serum and showed
that the heat-labile complement proteins C1 and C2 act sequentially and are required
for complement activity. The first heat-stable complement component identified was
C3, successfully removed from serum by use of cobra venom by Ritz in 1912, and
yeast cells by Coca in 1914. Although C4 was described by Gordon in 1926, the
correct sequence in which these four complement components reacted
(C1C4C2C3) was only established 30 years later by Ecker’s group. Until the
late 1950’s complement function was connected exclusively to complementing the
ability of the antibodies to cause a target lysis. Then Louis Pillemer suggested a
properdin-dependent but antibody-independent pathway of C activation. This
“alternative pathway” and its distinct protein constituents were fully elucidated and
accepted by the scientific community only in the 1970`s. At that time, the lytic activity
of C was shown to involve at least 11 different proteins. In recent years, a “lectin
pathway” of C activation, functioning through recognition of mannan polysaccharides
on microbial pathogens has been identified [the entire history is reviewed in
(Lachmann, 2006)].
These initial studies regarding complement were, therefore, dealing with bactericidal
activity against antibody-coated Gram-negative bacteria. Today, in addition to this
function, complement is known to act as an opsonin and an inducer of inflammation.
Its opsonin activity results in enhanced phagocytosis of the complement-tagged
microbes whereas its inflammatory activity is related to the attraction of immune cells
REVIEW OF THE LITERATURE
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along the gradient of complement cleavage products. The complement system
comprises approximately 35 fluid-phase (Table 1) and membrane-bound proteins. It is
activated via the classical, the alternative, and the lectin pathways, which sense
microbes by means of different recognition molecules. Once the complement is
activated, a cascade of proteolytic reactions leads to the cleavage of C3, which is a
converging stage for all three pathways. Subsequently, C3 cleavage is followed by the
lytic pathway and the generation of the membrane attack complex (MAC). MAC
forms a pore in the target cell and in consequence disrupts the membrane, causing the
cell death.
Table 1. Components of the complement system.
Component Structure Plasma conc.
(μg/ml)
Classical pathway
C1 3 subunits: C1q (460kDa), C1r (80kDa),
C1s (80kDa) in a complex (C1qr2s2)
180
C4 3 chains (, 97 kDa; , 75 kDa; , 33 kDa) 600
C2 single chain, 102 kDa 20
Alternative pathway
Factor B single chain, 93 kDa 210
Factor D single chain, 24 kDa 2
Properdin oligomers of 53-kDa chains 5
Lectin pathway
MBL polymer of 32-kDa chains 0-5
MASP-1 single chain, 100 kDa 1.5-12
MASP-2 single chain, 76 kDa ND
Common:
C3 2 chains: , 110 kDa; , 75 kDa 1300
Terminal pathway
C5 2 chains: 115 kDa, 75 kDa 70
C6 single chain, 120 kDa 65
C7 single chain, 110 kDa 55
C8 3 chains: , 65 kDa; , 65 kDa; , 22 kDa 55
C9 single chain, 69 kDa 60
MBL, mannose-binding lectin; MASP, mannose-binding lectin-associated serine protease; ND, non-
detectable
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1.2.1 Classical pathway (CP)
Binding of antibody to its specific antigen on the surface of a microbe opens up the
binding sites in the bound antibody for the classical pathway pattern recognition
molecule C1q. C1q, a 460-kDa multimeric protein, resembles in structure a bouquet of
six tulips with globular “head” domains and collagen-like triple-helical “stems”
(Calcott and Müller-Eberhard, 1972; Reid and Porter, 1976; Schumaker et al., 1982;
Strang et al., 1982). In the presence of Ca2+, C1q, together with two C1r and two C1s
serine protease molecules (C1qr2s2), forms the C1 complex (Busby and Ingham, 1990;
Loos et al., 1980; Thielens et al., 1990). Six globular heads of the C1q subunits
recognize Fc regions of IgM or multiple IgG molecules only when they are deposited
on a microbial surface (Ishizaka et al., 1966; Schumaker et al., 1986). C1q can also
activate the classical pathway via binding to C-reactive protein (CRP), nucleic acids,
LPS and immune complexes (Jiang et al., 1992a, 1992b; Loos, 1982; Nauta et al.,
2002).
C1q binding to a target causes a mechanical stress transmitted from the C1q stems to
C1r molecules (Gaboriaud et al., 2004), which in turn activates two molecules of C1s.
C1s first targets the C4 molecule (Patrick et al., 1970). C4 comprises three chains
linked together by disulfide bridges and an internal thioester group which upon
disruption mediates a covalent attachment to a microbial surface (Fig. 2) (Dodds et al.,
1996; Janatova and Tack, 1981; Schreiber and Müller-Eberhard, 1974). C1s-mediated
cleavage of C4 generates two fragments: a small C4a acting as an anaphylatoxin
(Gorski et al., 1979) and a larger C4b. C4b binds to the microbial surface, since the
exposed thioester group is prone to hydrolysis (Law and Dodds, 1990, 1997), and acts
as the C2 receptor in the presence of Mg2+ (Fig. 1). C2 becomes susceptible to C1s and
is cleaved into C2a and C2b (Nagasawa and Stroud, 1977). C2a remains complexed
with C4b, whereas C2b is released in the microenvironment. C4b2a complex is known
as the classical pathway C3 convertase (Kerr, 1980), in which the catalytic subunit C2a
cleaves C3 (Fig. 1).
REVIEW OF THE LITERATURE
- 7 -
C3 is the most abundant complement protein in serum. It consists of a 119-kDa -
chain and a 75-kDa -chain linked together by a single disulfide bond and non-
covalent forces (Fig. 2) (Lambris, 1988). Similarly to C4, C3 possesses an internal
thioester bond hidden within a hydrophobic pocket in native C3 (Janssen et al., 2006;
Law and Dodds, 1990, 1997). Upon C3 cleavage at a single site on the -chain, C3a,
called anaphylatoxin, is released into the environment (Hugli, 1975), while C3b binds
to nearby surfaces via an exposed thioester (Law and Levine, 1977; Law and Dodds,
1997; Sim et al., 1981). Some of the C3b binds to CP C3 convertase (C4b2a) to form
C4b2a3b complex, which is termed the CP C5 convertase (Fig. 1) (Takata et al.,
1987).
Alternative PathwayClassical Pathway
C1
Lectin Pathway
MBL-MASP      C3b
C4
C4bC2
C4b2a
(C3 convertase)
C4
C4bC2
     C3bB
FactorD
Properdin
C3bBb
(C3 convertase)
C3 C3C3b
C4b2a3b
(C5 convertase)
C3bBb3b
(C5 convertase)
C5 C5C5b
MAC
C6-C9
Figure 1. Schematic overview of the complement activation cascade (modified from Miwa and
Song, 2001).
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1.2.2 Alternative pathway (AP)
The activation of the alternative complement pathway begins with the activation of C3
and it requires factors B and D, properdin, and Mg2+, all of which are present in
normal serum (Fig. 1). The classical pathway is not the only source of the C3b
participating in activation of the alternative pathway. C3b is also generated
spontaneously by hydrolysis of the internal thioester bond in the native fluid phase C3
(tick-over mechanism) (Lachmann and Hughes-Jones, 1984). Native C3 is hydrolyzed
to an active intermediate known as C3(H2O) (Pangburn et al., 1981). C3(H2O) binds
factor B, making the latter susceptible to cleavage by factor D (Lesavre and Müller-
Eberhard, 1978). Factor D is a serine protease and cleaves Factor B into Ba and Bb.
Generated C3(H2O)Bb complex acts as the fluid phase alternative pathway C3
convertase. Fluid phase C3b, generated by the convertase, is deposited on a bacterial
surface via its thioester group exposed on that surface (Law and Dodds, 1990, 1997).
In the presence of Mg2+ it forms a complex with factor B (Fig. 1). The resulting C3bB
is activated to become AP C3 convertase, C3bBb, by factor D and is stabilized by
properdin (Fig. 1).
AP convertases are crucial for the C3b amplification loop (Fig. 3). The serine protease
Bb of the AP convertase very efficiently degrades C3, generating large amounts of
C3b, which in turn can become deposited on nearby surfaces or contribute to C5
convertase formation via binding to C3 convertases of AP and CP. In consequence, the
AP amplifies activation of the CP (Lachmann and Hughes-Jones, 1984).
1.2.3 Lectin pathway (LP)
The C4 activation can also be achieved without the participation of the antibodies and
C1 via the lectin pathway. This pathway is initiated by MBL and the MBL-associated
serine proteases: MASP-1 and MASP-2 (Sato et al., 1994; Thiel et al., 1997). MBL
binds to certain mannose residues on many bacteria and subsequently interacts with
MASP-1 and MASP-2. The MBL-MASP1-MASP2 complex is analogous to the C1
complex of the classical pathway. A major difference is, however, that C1 binds solely
to a target tagged with specific antibodies, while MBL binds directly to mannose- or
N-acetyl-glucosamine-rich polysaccharides commonly presented by a wide range of
microorganisms (Jack et al., 2001). Upon activation, the MASPs cleave the
downstream complement components C4 and C2 (Matsushita and Fujita, 1992; Thiel
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et al., 1997). From this point onwards, the lectin pathway is identical to the classical
pathway (Fig. 1).
1.2.4. Lytic pathway
The classical, lectin, and alternative pathways end with the formation of C5 convertase
that then leads to the assembly of MAC via the lytic pathway. C5 convertases
(C3b4b2a, C3bBbC3b) generated by one of the pathways cleave C5 (Fig. 1) (Cooper
and Müller-Eberhard, 1970; DiScipio et al., 1983). C5 comprises two chains linked
together with one disulfide bond. C5, however, lacks the internal thioester group
characteristic of C3 and C4 (DiScipio et al., 1983). C5 cleavage generates two
biologically active fragments: C5a, a potent chemokine, and anaphylatoxin (Cochrane
and Müller-Eberhard, 1968; Ward and Newman, 1969), and C5b, an initial constituent
in MAC assembly (Fig. 1).
C5b is very labile and needs to bind to C6 very rapidly (DiScipio et al., 1983). C5b6
subsequently binds C7 to yield the hydrophobic C5b67 complex (DiScipio et al., 1988;
DiScipio, 1992). The C5b67 complex attaches to nearby membranes without harming
the cells. Upon C8 binding, the resulting C5b678 complex inserts deeply into the
membrane (Kolb and Müller-Eberhard, 1973; Tamura et al., 1972) and subsequently
binds C9, causing its nonenzymatic polymerization (Tschopp et al., 1982b). In
consequence, C9 undergoes hydrophilic-amphiphilic and conformational transition to a
tubular structure (Tschopp et al., 1982a). Acquisition of C9 molecules leads to the
formation of a pore-like structure of MAC which passes through the membrane
(Tschopp et al., 1982a). The pore is approximately110 Å wide (Podack and Tschopp,
1982) and has a hydrophilic lumen through which, according to the “doughnut theory”,
cell contents leak out and water is drawn inside, generating the osmotic pressure which
causes rupture of cellular membranes (Lachmann, 2006). In addition, leakage through
the pore may be assisted by passage of the solutes and water through the “leaky
patches” formed in the membrane upon MAC insertion (Lachmann, 2006).
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Table 2. Fluid-phase regulators of the complement system
Regulator Size
(kDa)
Serum
conc.
(μg/ml)
Function Reference
C1 inhibitor
(C1-INH)
105 200 blocks active sites on C1s ans C1r or
removes them from the C1 complex
prevents C1 autoactivation
inhibits formation of AP C3
convertase
Harrison, 1983;
Harpel and Cooper,
1975; Ziccardi and
Cooper, 1979;
Ziccardi, 1982, 1985;
Jiang et al., 2001
FH 150 500 accelerates decay of  AP C3
convertase
inhibits formation of AP C3
convertase
cofactor for FI
Nilsson and Müller-
Eberhard, 1965;
Pangburn et al.,
1977; Weiler et al.,
1976; Whaley and
Ruddy, 1976
C4bp 570 200 accelerates decay of CP/LP C3
convertase
inhibits formation of CP/LP C3
convertase
cofactor for FI
Barnum, 1991; Gigli
et al., 1979;
Dahlbäck, 1983
FI 90 30 cleaves C3b and C4b in the
presence of cofactor
Ruddy and Austen,
1969; Ahearn and
Fearon, 1989
Properdin 210 26 stabilizes AP C3 convertase Fearon and Austen,
1975; Medicus et al.,
1976; Smith et al.,
1984
Clusterin
(SP40,40)
(Apolipoprotein
J)
70 50 prevents MAC insertion by binding to
terminal complement complexes
C5b-7, C5b-8, and C5b-9
Tsuruta et al., 1990;
Choi et al., 1989;
Murphy et al., 1989;
Tschopp et al., 1993
Vitronectin
(S-protein)
75 500 prevents MAC insertion by binding to
terminal complement complexes
C5b-7
Podack and Müller-
Eberhard, 1979
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1.3 Complement regulation
1.3.1 Fluid-phase complement regulators
Tight regulation of the complement system crucial in preventing bystander injury of
host cells and systemic depletion of complement, is provided by fluid phase
complement regulators (Table 2). These regulate complement activation at C1 (C1
inhibitor), C3 (factor H, C4b-binding protein, properdin) or MAC (clusterin,
vitronectin) levels. The complement inhibitors that act at the C3 level function as
cofactors for serine protease FI-mediated cleavage of C3b and C4b. In this way, they
prevent formation of C3 convertases or downregulate their activity. The latter
function, termed decay-accelerating activity, relies on displacing the C3 convertase
enzymatic subunits C2a or Bb.
1.3.1.1 Factor I
FI is a 90-kDa (heavy chain, 50 kDa; light chain, 38 kDa) plasma protease which
circulates in its active form at a concentration of 30 μg/ml (Ruddy and Austen, 1969).
It cleaves arginyl bonds of its substrates C3b and C4b only when these are complexed
to one of the complement regulators. Membrane cofactor protein (MCP), complement
receptor type 1 (CR1), and C4bp contribute to the cleavage of both C3b and C4b,
whereas FH exclusively participates in the cleavage of C3b (Ahearn and Fearon, 1989;
Blom et al., 2003; Fujita and Nussenzweig, 1979; Pangburn et al., 1977; Seya et al.,
1986).
Inactivation of C3b by FI can occur at three sites of the ’-chain and results in the
generation of iC3b1, iC3b2, C3c or C3dg (Fig. 2A) (Davis and Harrison, 1982; Lambris
et al., 1996; Medicus et al., 1983; Ross et al., 1982). The latter two products are
generated when CR1 serves as a co-factor (Ahearn and Fearon, 1989). FI-mediated
inactivation of C4b targets two sites of the -chain and results in the generation of C4c
and C4d fragments (Fig. 2B).
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Figure 2. Schematic representation of C3 (A) and C4 (B) cleavage sites (modified from
Morgan, 2000; Sahu and Lambris, 2001)
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B.
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1.3.1.2 Factor H protein family
1.3.1.2.1 Factor H
FH was identified as a 1H globulin by Nilsson and Müeller-Eberhard (Nilsson and
Müller-Eberhard, 1965). It is a soluble single-chain glycoprotein of 150 kDa present in
plasma at a concentration of 500 μg/ml. FH accelerates the decay of the AP C3
convertase, competes with FB for C3b binding, and acts as a cofactor for FI-mediated
C3b inactivation (Fig. 3) (Pangburn et al., 1977; Weiler et al., 1976; Whaley and
Ruddy, 1976). In this way, FH downregulates complement in the fluid phase and on
cell surfaces.
FH distinction of self from non-self (AP activators) surfaces is based on recognition of
polyanionic substances such as sialic acids and glycosaminoglycans (Fearon, 1978;
Meri and Pangburn, 1990). These coat the host cells but, in general, do not cover
foreign cell membranes. High-affinity interaction between FH and C3b occurs when
the latter is accompanied by polyanions and results in the inhibition of AP. In the
Figure 3. FH and C4bp control steps. Solid lines, complement activation; dashed lines,
complement inhibition
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absence of polyanions, however, FH affinity for C3b dramatically decreases, and in
consequence AP activation proceeds (Kazatchkine et al., 1979; Pangburn et al., 1983).
FH is composed of 20 SCRs joined by short linker regions of 3-8 amino acids. SCRs
are arranged in a continuous fashion and resemble a string of beads (Discipio, 1992;
Ripoche et al., 1988). SCRs 1-4, SCRs 12-14, and SCRs 19-20 provide the binding
sites for C3b, whereas SCR7, SCR 13, and SCRs 19-20 bind heparin and polyanions
(Alsenz et al., 1985; Blackmore et al., 1996, 1998b; Gordon et al., 1995; Jokiranta et
al., 1996, 2000; Kühn et al., 1995; Pangburn et al., 1991; Prodinger et al., 1998;
Sharma and Pangburn, 1996). Decay-accelerating and cofactor functions have been
ascribed to SCRs 1-4 (Gordon et al., 1995; Kühn et al., 1995; Kühn and Zipfel, 1996)
(Fig. 4).
Deficiency of FH in humans has been associated with membranoproliferative
glomerulonephritis (MPGN) and atypical hemolytic uremic syndrom (aHUS).
Complete FH deficiency is, however, a rare phenomenon (Reis et al., 2006). Missense
mutations clustered within SCRs 19-20 have been exclusively linked to aHUS (Ault,
2000; Dragon-Durey et al., 2004; Jokiranta et al., 2006; Manuelian et al., 2003;
Figure 4. FH protein family (modified from Jozsi et al., 2005; Zipfel et al., 2002). SCRs are
aligned according to regions of homology. Binding sites for C3b and heparin are shown for
FH and FHL-1.
REVIEW OF THE LITERATURE
- 15 -
Neumann et al., 2003; Zipfel, 2001), a rapidly progressing renal disease that manifests
as an endothelial cell damage, hemolysis, massive AP activation, and kidney failure
(Ruggenenti et al., 2001). As the C terminus is crucial for binding to C3b, C3d,
heparin, and polyanions, mutation within the C-terminal SCRs abolishes critical FH
functions for complement regulation.
1.3.1.2.2 Factor H-like protein (FHL-1)
FHL-1 (reconectin) is an alternatively spliced product of the FH-encoding gene
(Estaller et al., 1991). It comprises seven SCRs, being identical to the first seven N-
terminal SCRs of FH and the unique C-terminal sequence of four amino acids (Fig. 4).
Thus, FHL-1, similar to FH, displays cofactor and decay-accelerating activities and
possibly contributes to complement regulation in vivo (Kühn and Zipfel, 1996; Zipfel
and Skerka, 1999). However, the plasma concentration of this 42 kDa protein is
approximately one-tenth that of FH.
1.3.1.2.3 Factor H-related proteins (FHR)
FHRs are encoded by separate genes located within the regulators of complement
activation (RCA) gene cluster on chromosome 1 (Zipfel et al., 1999). To date, five
human FHRs have been identified, and these share structural similarities with FH (Fig.
4). FHR-1 consists of five SCRs and is found in the 37-kDa (FHR1-) or 43-kDa
(FHR1-) forms with one or two carbohydrate-side residues, respectively (Estaller et
al., 1991; Skerka et al., 1991). FHR-2 is composed of four SCRs and exists in a
glycosylated (29-kDa) or in a non-glycosylated (24-kDa) form (Skerka et al., 1992).
FHR-3 and FHR-4B are similar to each other and are organized into five SCRs. FHR-3
occurs in several glycosylated forms in human plasma (ranging from 35 kDa to 56
kDa), whereas FHR-4B, a 42-kDa protein, is one of the two FHR-4 gene products
derived by means of alternative splicing (Jozsi et al., 2005; Skerka et al., 1993, 1997).
The other product of the FHR-4 gene is FHR-4A. This glycosylated protein of 86 kDa
consists of nine SCRs, due to duplication of four SCRs (Fig. 4) (Jozsi et al., 2005).
FHR 5 contains nine SCRs homologous to those of FH (McRae et al., 2001).
The structural similarity between FHR proteins and FH suggests that FHRs share some
of the FH activities. Indeed, FHR-3, FHR-4, and FHR-5 have been shown to bind C3b
while FHR-1, FHR-3, and FHR-5 bind heparin (Hellwage et al., 1999; McRae et al.,
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2001, 2005; Prodinger et al., 1998). In addition, FHR-3 and FHR-4 have been
suggested to modify the conformation of C3b to enhance FH cofactor activity
(Hellwage et al., 1999). FHR-5 is a relatively weak cofactor for FI; it is able, however,
to inhibit the C3 convertase activity (McRae et al., 2005).
1.3.1.3 C4b-binding protein
C4bp is a large (570 kDa), spider-like glycoprotein (Chung et al., 1985; Dahlbäck,
1983; Dahlbäck et al., 1983), present in plasma at a concentration of 200 μg/ml. It
circulates complexed with the vitamin K-dependent protein S. Protein S, bound to
SCR1 of the C4bp -chain (Härdig et al., 1993; Härdig and Dahlbäck, 1996), does not
display its anticoagulant function (Dahlbäck, 1986). It can, however, direct C4bp to
negatively charged surfaces and apoptotic cells (Schwalbe et al., 1990; Webb et al.,
2002).
C4bp consists of seven identical -chains (70 kDa) and one -chain (45 kDa) (Hillarp
and Dahlbäck, 1990). The - and -chains are composed of eight and three SCRs,
respectively (Fig. 5). These chains are linked together by disulfide bonds at their most
C-terminal parts (Kask et al., 2002).
1
2
3
4
5
6
7
8
N
-chain
-chain
C4b/heparin binding sites
Figure 5. Schematic structure of C4bp (modified from Blom et al., 2004). Binding sites for
C4b indicated.
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C4bp down-regulates complement activity (Fig. 3), acting as a fluid-phase inhibitor of
the classical and lectin pathway activation steps that involve C4b (Barnum, 1991).
High C4bp concentrations, however, can also force decay of AP C3 convertase (Blom
et al., 2003). N-terminal SCRs 1-3 of C4bp -chains bind C4b (Kask et al., 2002),
which renders C4b susceptible to FI-mediated cleavage (Fig. 2). In addition, C4bp
prevents the assembly of the CP C3-convertase (C4b2a) and accelerates a natural
decay of the preformed convertase by forcing C2a dissociation from the complex
(Gigli et al., 1979). Heparin can disturb the interaction between C4bp and C4b because
it also binds SCRs 1-3 of C4bp -chains (Blom et al., 2001; Hessing et al., 1990).
1.3.2 Membrane-bound complement regulators
In addition to fluid phase regulators, cells are equipped with membrane-bound
complement inhibitors that block complement activation at C3 (DAF, MCP, CR1) or
MAC level (CD59) (Morgan and Harris, 1999). Some pathogens, however, use these
membrane-bound regulators for adhesion or invasion, or both, because they are widely
expressed by human cells (Table 3).
1.4 Functions of the complement system
1.4.1 Opsonin-mediated clearance of microbes and host debris
A crucial complement function is to facilitate the phagocytosis of pathogens and the
clean-up of host cell debris. Phagocytic cells are known to bear complement receptors
such as CR1 (CD35), CR3 (CD11b/CD18), and CR4 (CD11c/CD18). CR1 recognizes
the targets coated with C1q, C3b, C4b, and iC3b, whereas the latter two are iC3b-
specific (Klickstein et al., 1988, 1997; Krych et al., 1992; Krych-Goldberg and
Atkinson, 2001; Newman et al., 1984). These opsonins immobilize microbes on the
phagocytic cell surface, which ensures their efficient uptake and destruction.
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Immune complexes, small and soluble antigens derived from antigen-antibody
complexes, are found in the circulation after most infections. C1q binds to immune
complexes or to blebs of apoptotic cells (Korb and Ahearn, 1997; Navratil et al.,
2001). C1q initiates the complement activation on their surfaces and that results in the
deposition of C3b and C4b (Nauta et al., 2002). Apoptotic cells are subsequently
recognized by tissue macrophages and phagocytosed. Ligation of C3b and C4b
deposited on the immune complexes with CR1 on erythrocytes initiates removal of the
complexes from the circulation (Schifferli et al., 1986). Erythrocytes carry this cargo
to the liver and spleen to finally pass it on to macrophages.
1.4.2 Direct lysis of pathogens
Activation of the complement system leads to the generation of MAC on the surface of
target cells, thus causing their death. The complement system by this means plays an
important role in host defense against Gram-negative bacteria. Gram-positive bacteria
are, however, resistant to direct killing mediated by complement. A thick and
impenetrable peptidoglycan layer protects the cytoplasmic membrane of Gram-positive
bacteria from such MAC-induced damage. Although the complement system does not
directly kill Gram-positive bacteria, it still controls the course of Gram-positive
infections by its ability to opsonize and tag the microbes for phagocytic destruction
(Moffitt and Frank, 1994).
1.4.3 Induction of inflammation
Complement cleavage fragments such as C3a, C4a, and C5a are able to induce a local
inflammatory response (Hugli, 1981). Of the three, C5a has the highest inflammation-
inducing activity. These anaphylatoxins act as stimulators and chemoattractants for
those myeloid cells bearing anaphylatoxin-specific receptors. In addition, they act on
blood vessels, increase vascular permeability, and induce endothelial cells for
expression of adhesin molecules (DiScipio et al., 1999; Foreman et al., 1996; Gerard
and Gerard, 1994). This all contributes to a rapid recruitment of phagocytic cells to the
site of inflammation and promotes clearance of pathogens.
1.4.4 Shaping the specific immune response
Complement-derived fragments influence the antibody response of adaptive immunity.
CD19 and CD21 (CR2) are constituents of the B cell co-receptor complex. Binding of
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C3d to CD21 triggers CD19-mediated signaling, and this leads to B cell activation
(Dempsey et al., 1996; Dempsey and Fearon, 1996). In addition, the -chain of C4bp
can activate B cells via the CD40 receptor in a manner similar to that of CD40L
(Brodeur et al., 2003).
1.5 Bacterial mechanisms of complement evasion
Pathogenic microbes have developed a range of strategies to evade complement-
mediated recognition and destruction. To achieve this goal, they have equipped
themselves with surface factors which either directly interfere with the complement
activation or bind host complement regulatory proteins. Microbial complement-
evasion strategies include interference with the initial complement activation, with C3
convertase functions, or with MAC insertion.
1.5.1 Interference with initial complement activation
1.5.1.1 Binding of immunoglobulins via Fc portion
Some microbes interfere with classical pathway activation via binding of the
immunoglobulin Fc portion, e.g., protein G of streptococci or protein A of
Staphylococcus aureus (Björck and Kronvall, 1984; Forsgren and Sjöquist, 1966).
Because the ligation of the Fc receptor on phagocytic cells with the Fc region of target-
bound IgG leads to efficient phagocytosis, blocking of the Fc portion by protein A
inhibits this process (Foster, 2005). In addition, it interferes with C1q binding to IgG,
thereby inhibiting complement activation (Laky et al., 1985).
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1.5.1.2 Immunoglobulin and C3/C3b degradation
Several microbes directly or by use of host factors degrade immunoglobulins and
C3/C3b and block the complement activation. Cysteine proteinases, IdeS (IgG-
degrading enzyme of Streptococcus pyogenes) and SpeB (streptococcal pyrogenic
exotoxin B), of group A streptococci remove the Fc portion of bacterium-bound IgG
(von Pawel-Rammingen and Björck, 2003). Porphyromonas gingivalis prtH-encoded
protease degrades both IgG and C3 (Schenkein et al., 1995), whereas S. aureus
degrades these complement-activation initiators indirectly. S. aureus first binds host
plasminogen and converts it to plasmin with the help of staphylokinase. In
consequence, plasmin attached to the bacterial surface cleaves both: C3b and IgG
(Rooijakkers et al., 2005b). Yeast, Candida albicans, proteinases can also degrade C3
and IgG and prevent complement activation (Kaminishi et al., 1995).
1.5.1.3 Binding of C1 inhibitor or C1q inhibition
The binding and utilization of C1 inhibitor (C1INH) occurs for several bacteria.
Enterohemorrhagic E. coli O157:H7 secretes StcE, a protease of C1-INH. StcE recruits
C1-INH to the cell surface and cleaves it to potentiate its ability to inhibit CP (Lathem
et al., 2004). This prevents complement activation and in consequence may restrict an
inflammatory response at the infection site. In addition, Bordetella pertussis, the
etiological agent for whooping cough, recruits C1-INH from human serum to prevent
its own destruction (Marr et al., 2007). Another mechanism to block the CP activation
at C1 level has been reported to take place in helminthic parasites. Paramyosins from
Taenia solium and Schistosoma mansoni bind C1q, block its activity, and prevent
complement activation at its very early stage (Laclette et al., 1992).
1.5.2 Inhibition of C3 convertases
1.5.2.1 Microbial factors directly interfering with C3 convertases
Some pathogens directly interfere with C3 convertase function. Staphylococcal
complement inhibitor (SCIN) is a secreted protein that binds to AP- and CP/LP-C3
convertases, impairing their enzymatic activity. Because such binding stablilizes C3
convertases, it also prevents the formation of new convertases (Rooijakkers et al.,
2005a). Another mechanism is exploited by group A streptococci. SpeB degrades host
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serum properdin to inhibit the formation of functional AP C3-convertase and resist
opsonophagocytosis (Tsao et al., 2006). Some microbes also disassemble C3
convertases. Herpes simplex virus (HSV) type 1 expresses the glycoprotein gC-1
which accelerates decay of the pre-formed C3 convertase. In addition, gC-1 binds C3b
and blocks its interaction with properdin, thereby inhibiting formation of AP C3
convertase (Fries et al., 1986; Kostavasili et al., 1997).
1.5.2.2 Microbial factors mimicking FI-cofactors to accelerate decay of the C3
convertases
Some microorganisms mimic the host cofactors for FI-mediated cleavage of C3b and
prevent their own destruction by using a mechanism similar to that exploited by
mammalian cells. Trypanosoma cruzi, a causative agent of Chagas disease, expresses a
glycoprotein gp160 that is functionally and genetically similar to DAF; gp160 is GPI-
anchored, accelerates decay of C3 convertase, and has a coding sequence displaying
60% similarity to the DAF-encoding gene (Norris et al., 1991).  On the other hand,
the amino acid sequence of the vaccinia virus C-control protein (VCP) shows
homology to the C4bp sequence. This accounts for a functional similarity between the
two proteins; SCR-composed VCP binds C4b, prevents formation of CP C3
convertase, and in addition accelerates decay of pre-formed convertases (Kotwal and
Moss, 1988; Kotwal et al., 1990).
1.5.2.3 Microbial factors binding host complement regulators
Pathogens that do not express surface factors that mimick host regulatory proteins
often interact with host complement regulators to protect their own surfaces. Several
microorganisms bind specific fluid-phase regulators, such as FH, FHL-1 and C4bp that
trigger C3 convertase decay and C3b/C4b inactivation.
Pathogens that acquire FH or FHL-1 gain an ability to disassemble AP C3 convertases
and to degrade any C3b deposited on their surfaces. The interaction of FH with the
sialic acid-covered host cells is known to block AP activation (Fearon, 1978). To bind
FH, pathogens such as group B streptococci (Marques et al., 1992) and N .
gonorrhoeae (Ram  et al., 1998b) cover their surfaces with sialic acid whereas
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trypomastigotes of T. cruzi express an unusual cell-surface trans-sialidase that enables
the parasite to sialylate its surface rapidly (Tomlinson et al., 1994).
Bacterial surface proteins also exist that are able to bind to FH, to FHL-1, or both.
BbCRASP-3 to -5 of Borrelia burgdorferi (Kraiczy et al., 2001), the  protein of
group B streptococcus (Areschoug et al., 2002), Por1A of N. gonorrhoea (Ram et al.,
1998a), or Hic and PspC of Streptococcus pneumoniae (Dave et al., 2001; Janulczyk et
al., 2000) bind FH, whereas BaCRASP-3 of Borrelia afzelii can interact with FHL-1
(Kraiczy et al., 2001). Some microbial proteins bind both FH and FHL-1. These
include M protein and fibronectin-binding protein (Fba) of S. pyogenes (Horstmann et
al., 1988; Kotarsky et al., 2001; Pandiripally et al., 2002) and BbCRASP-1 and
BbCRASP-2 of B. burgdorferi (Kraiczy et al., 2001).
FH-binding sites have been identified for several of these proteins (Fig. 6): BbCRASP-
1, -3 and -5 engage the C terminus;  protein, PspC, and Hic bind to the middle part;
and M protein and Fba interact with the N-terminal region of FH (Blackmore et al.,
1998a; Dave et al., 2004; Duthy et al., 2002; Jarva et al., 2002, 2004; Kotarsky et al.,
1998; Kraiczy et al., 2001; Pandiripally et al., 2003).
Several microbes express surface proteins snatching the host CP/LP regulator, C4bp,
to accelerate decay of CP C3 convertase and degrade C4b deposited on the microbial
surface. These proteins include the M protein of S. pyogenes, Por1A and Por1B of N.
gonorrhoeae, OmpA of E. coli K1, UspA1 and UspA2 of Moraxella catarrhalis, and
FHA of Bordetella pertussis (Berggård et al., 1997; Johnsson et al., 1996; Nordström
Figure 6. Schematic representation of factor H domains interacting with microbial surface
proteins (modified from Zipfel et al., 2002).
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et al., 2004; Prasadarao et al., 2002; Ram et al., 2001). Most of the C4bp-binding
proteins interact with the very N-terminal SCRs of C4bp -chains, whereas UspA-1
and UspA-2, in addition to N-terminal SCR2, bind C-terminal SCR5 and SCR7 (Fig.
7) (Accardo et al., 1996; Berggård et al., 2001; Nordström et al., 2004; Prasadarao et
al., 2002; Ram et al., 2001).
1.5.3 Interference with MAC formation (terminal pathway)
1.5.3.1 Physical barriers
Gram-positive bacteria are resistant to complement-mediated killing due to the
presence of thick peptidoglycan layer that prevents access of C5b-9 to the cytoplasmic
membrane (Joiner et al., 1983). Also long O-polysaccharide side chains of Salmonella
minnesota interfere with MAC insertion into the outer bacterial membrane. C5b-9 is
generated on the distal parts of LPS molecules which sterically hinder access of MAC
to the outer membrane (Joiner et al., 1986).
Figure 7. Schematic representation of C4bp domains interacting with microbial surface
proteins (modified from Blom et al., 2004). Binding sites for bacterial factors on C4bp -
chains indicated.
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1.5.3.2 Microbial proteins interfering with membrane attack complex
Resistance to the final step of the complement cascade is a prerequisite for the
resistance of Gram-negative bacteria to complement-mediated cytolysis. One example
of protein strongly inhibiting the terminal complement pathway is the E. coli outer
membrane protein TraT. It probably inhibits the formation of C5b-6 complex or causes
its structural alteration to render it nonfunctional (Pramoonjago et al., 1992). Another
example is B. burgdorferi CD59-like protein, which like human membrane-bound
CD59, prevents C9 polymerization and formation of MAC (Pausa et al., 2003).
1.5.3.3 Acquisition of host terminal pathway regulators
To date, few reports describe recruitment of normally membrane-bound terminal
pathway regulators from serum; for instance, E. coli and H. pylori bind CD59 from the
fluid phase to resist MAC-induced lysis (Rautemaa et al., 1998, 2001). On the other
hand, M. catarrhalis UspA2 binds a fluid-phase regulator, vitronectin, to block MAC
insertion into the cell membrane (Attia et al., 2006).
1.5.4 Interference with generation and function of complement-derived
chemoattractants
Gram-positive bacteria, though resistant to MAC-induced cytolysis, inhibit the
terminal pathway to prevent the release of complement chemoattractants such as C5a.
S. aureus, for example, produces a superantigen-related protein SSL7 that binds to C5
and in consequence blocks its cleavage into C5a and C5b (Langley et al., 2005). Group
A and Group B streptococci do not prevent C5 cleavage but inactivate the C5a formed.
Cell wall-anchored C5a peptidase expressed by these bacteria, though unable to cleave
the whole C5, efficiently cleaves C5a (Chmouryguina et al., 1996; Cleary et al., 1992;
Wexler et al., 1985; Wexler and Cleary, 1985). Another strategy to avoid C5a action
has been developed by S. aureus. It secretes CHIPS, an inhibitory protein, that binds to
receptors for C5a and formylated peptides (C5aR and FPR, respectively) on
phagocytic cells. This prevents the phagocytic cells from sensing the early signs of
bacterial infection such as C5a (de Haas et al., 2004).
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1.6 Genus Yersinia
Yersinae are Gram-negative rods belonging to the family Enterobacteriaceae. The
genus Yersinia comprises fourteen species. Three of them are human pathogens: Y.
pestis and the enteropathogens Y. pseudotuberculosis and Y. enterocolitica (Brubaker,
1991). All three species harbor a 70-kb virulence plasmid (pYV) essential for immune
evasion and survival in mammalian host (Cornelis et al., 1998) and commonly display
a tropism for lymphoid tissue (Brubaker, 1991). Enteropathogenic yersiniae are motile
at 25°C and non-motile at 37°C due to repression of fliA, the positive regulator of
flagellin streuctural genes. Y. pestis is non-motile regardless of the growth temperature
due to several mutations in falgellar genes (reviewed in (Minnich and Rohde, 2007). In
addition to its difference in motility, Y. pestis causes a distinctive disease and differs in
ecology and epidemiology from the enteropathogenic yersiniae.
1.6.1 Y. pestis
Y. pestis is a causative agent of plague, a systemic infection in mammals. Bubonic
plague is initiated by the bite of an infected flea. As the proventriculus of the flea is
blocked by Y. pestis aggregates, the flea regurgitates the bacterial mass into the bite
site when it attempts to feed (Bacot and Martin, 1914). By means of the flea bite,
bacteria are injected intradermally into the mammalian host, where they begin to
multiply at the site of infection. Via the lymphatic system and bloodstream, bacteria
disseminate to the lymph nodes (Perry and Fetherston, 1997). The bacteria multiply in
the lymph nodes and induce an inflammatory response resulting in swollen and painful
lymph nodes, termed buboes. As the infection proceeds, bacteria enter the
bloodstream, causing septicemia, and infect deeper organs, such as the liver and spleen
(Brubaker, 1991; Perry and Fetherston, 1997). When bacteria reach the lungs, the
disease takes the form of highly infectious pneumonic plague. Individuals with
pneumonic plague transmit the bacteria by spreading infectious droplets. Inhalation of
Y. pestis aerosols results in development of a pneumonic plague and death due to
rapidly progressing sepsis.
Y. pestis harbors, in addition to the pYV, common in enteropathogenic yersiniae, two
extra plasmids pMT1 (pFra) and pPla (pPCP1) (Hu et al., 1998; Lindler et al., 1998).
Ability to survive in the flea gut is provided by pMT1-encoded phospholipase D
(Yersinia murine toxin) while pPla-encoded plasminogen activator, Pla, is required for
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the bacteria to penetrate mammalian tissues and disseminate from the site of the
inoculum (Brubaker, 1991; Hinnebusch et al., 2002). Flea-borne transmission requires
a chromosomally located hemin storage locus (hms). Hms-encoded outer membrane
proteins contribute to biofilm formation and blocking of the flea proventriculus
(Hinnebusch et al., 1996).
The three biovars of Y. pestis are differentiated on the basis of their ability to ferment
glycerol and reduce nitrate: Antiqua, Mediaevalis and Orientalis. Historically, each
biovar is associated with one of the three pandemics, the Justinian plague (541-767)
has been assigned to the biovar Antiqua, the Black Death (1346-1850) to Mediaevalis
(Devignant, 1951; Guiyoule et al., 1994), and Biovar Orientalis is responsible for the
most recent plague epidemics (1894-present). This pandemic-biovar relationship has
been recently substantiated by ribotyping (Guiyoule et al., 1994) and by IS1 0 0
insertion element RFLP (restriction fragment length polymorphism) analyses of Y.
pestis strains (Achtman et al., 1999). Y. pestis strains subjected to comparative
sequencing analyses show negligible nucleotide variation, as Y. pestis is a recently
emerged pathogen (Achtman et al., 1999; Adair et al., 2000). However, IS100-based,
multi locus VNTR (variable-number tandem repeat) and single nucleotide
polymorphism (SNP) marker analyses provide the high resolution required for
estimation of genetic relationship of Y. pestis strains (Achtman et al., 1999; Adair et
al., 2000; Touchman et al., 2007).
1.6.2 Enteropathogenic Yersiniae
The enteropathogenic Yersiniae are widespread. Yersiniae infect an array of animal
hosts, including mammals and avian species. Y. pseudotuberculosis and  Y.
enterocolitica are usually acquired by ingestion of contaminated food or water (Naktin
and Beavis, 1999). They pass through the acidic content of the stomach and reach the
small intestine. There, they are shuttled across the intestinal epithelium by the M cells
of Peyer’s patches and gain access to subepithelial space (Autenrieth and Firsching,
1996; Marra and Isberg, 1997; Simonet et al., 1990). Subsequently, the bacteria reach
the mesenteric lymph nodes and in some cases spread further to the liver and spleen,
where they multiply and induce an inflammatory response resulting in gastroenteritis
with mesenteric lymphadenitis and terminal ileitis. Y. enterocolitica due to expression
of the heat-stable toxin (Yst) causes more severe and often bloody diarrhea in children
than does Y. pseudotuberculosis (Delor and Cornelis, 1992). Although the disease is
REVIEW OF THE LITERATURE
- 28 -
mostly self-limiting and restricted to the gastrointestinal tract, bacteria may
occasionally induce secondary post-infectious sequelae such as arthritis, erythema
nodosum, myocarditis or glomerulonephritis (Baba et al., 1991; Bottone, 1997;
Davenport et al., 1987; Krober et al., 1983; Leino et al., 1980; Takeda et al., 1991;
Tertti et al., 1984).
1.6.2.1 Y. pseudotuberculosis
Both Y. pseudotuberculosis and Y. enterocolitica are soil- and water-borne
enteropathogens causing gastroenteritis. Y. pestis, which causes a distinct disease, and
is an obligate pathogen found solely in arthropod vectors and mammalian hosts, is
paradoxically very closely related to Y. pseudotuberculosis. In fact, population genetic
studies have suggested that Y. pestis evolved from Y. pseudotuberculosis 9,000 to
40,000 years ago (Achtman et al., 1999; Achtman, 2004). Furthermore, Y. pestis and Y.
pseudotuberculosis genome sequences show nearly 97% homology (Chain et al.,
2004). As the LPS O-ag gene cluster of Y. pseudotuberculosis serotype O:1b shows
98.9% identity to the cryptic O-ag gene cluster of Y. pestis, evidence is strong, that the
plague bacterium evolved from Y. pseudotuberculosis serotype O:1b (Skurnik et al.,
2000). Y. pseudotuberculosis  is grouped into 21 serotypes based on differences in LPS
O-ag profiles (Skurnik et al., 2000). Based on the distribution of superantigen toxins
(YPMa-c), high-pathogenicity island (HPI) and R-HPI (only the right-hand part of the
HPI present), Y. pseudotuberculosis strains can be further divided into six (genetic)
subgroups (Fukushima et al., 2001) (Table 4). Serotypes of subgroups 1, 3, and 4 are
predominantly found in the Far East (Russia, China, Korea, and Japan); serotypes of
subgroup 2 in the West (Europe, America, Australiasia); and strains belonging to
subgroups 3 and 5 can be isolated throughout the world.
Many of the insecticidal toxin genes occur in Y. pseudotuberculosis, which has, among
Enterobacteriaceae, a unique ability to infect fleas. Interestingly, in Y. pestis many
insecticidal toxin genes are pseudogenes (Hinchliffe et al., 2003; Parkhill et al., 2001)
because the plague bacterium has to persist in the flea gut and needs the living flea for
its life cycle.
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Y. pseudotuberculosis
non-pathogenic low-pathogenic pathogenic
subgroups
4 5 1 3 2 6
YPMb+ YPMc+ YPMa+ YPM-
HPI- R-HPI+ HPI+ HPI- HPI+ HPI-
pYV- pYV+ pYV+ pYV+ pYV+ pYV+
Serotypes
O:1b
O:5a
O:5b
O:6
O:7
O:9
O:10
O:11
O:12
O:3 O:1b
O:3
O:5a
O:5b
O:1b
O:2a
O:2b
O:2c
O:3
O:4a
O:4b
O:5a
O:5b
O:6
O:10
O:1a
O:1b
O:1b
O:2a
O:2b
O:2c
O:3
O:4a
O:4b
O:5a
O:5b
O:6
O:7
O:11
O:13
1.6.2.2 Y. enterocolitica
Y. enterocolitica has evolved independently from Y. pseudotuberculosis and Y. pestis
(Wren, 2003). Based on their biochemical heterogeneity, six Y. enterocolitica
biogroups are identifiable (Table 5). Non-pathogenic bacteria lacking the pYV belong
to the biogroup 1A, whereas pathogenic pYV-bearing Y. enterocolitica are divided into
two lineages: low-virulence bacteria including biogroups 2 to 5 (non-lethal in mice)
Table 4. Y. pseudotuberculosis subgroups (modified from Fukushima et al., 2001).
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and high-virulence biogroup 1B (lethal in mice) (Bottone, 1997). These biogroups
differ in their geographic distribution; strains belonging to biogroup 1B are found
predominantly in North America, biogroups 2 to 5 strains mainly in Europe and Japan,
and strains belonging to biogroup 1A are distributed throughout the world (Bottone,
1997). These biogroups are further subgrouped into serotypes based on variation in the
LPS O-ag (Table 5).
Y. enterocolitica
avirulent low virulence
high
virulence
biogroups
1A 2 3 4 5 1B
serotypes
O:5
O:6,30
O:7,8
O:18
O:46
O:9
O:5,27
O:1,2,3
O:5,27
O:3 O:2,3 O:8
O:4
O:13a,b
O:18
O:20
O:21
1.6.3 Virulence determinants of pathogenic Yersiniae
The three pathogenic Yersinia species require a 70-kb virulence plasmid (pYV),
encoding the proteins of the type III secretion system for full virulence (Viboud and
Bliska, 2005). However, pYV, although necessary, alone is not sufficient to cause
disease (Heesemann and Laufs, 1983; Heesemann et al., 1984). Yersinia pathogenesis
additionally involves multiple genes located in the chromosome of the bacterium.
Since Y. enterocolitica and Y. pseudotuberculosis lifestyle differs dramatically from
that of Y. pestis, several plasmid- and chromosome-located genes required for
enteropathogenicity are pseudogenes in the plague bacterium (Tables 6 and 7).
Table 5. Y. enterocolitica biogroups and serotypes (modified from Bottone, 1999).
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1.6.4 Y. enterocolitica surface factors shaping serum resistance phenotype
1.6.4.1 YadA
YadA, formerly known as Yop1 or P1, forms lollipop-like structures (approx. 30 nm or
23 nm in length in Y. enterocolitica serotypes O:3 and O:8, respectively) on the surface
of enteropathogenic Yersiniae (Bölin et al., 1982, 1985; Hoiczyk et al., 2000). YadA is
the most important virulence factor of Y. enterocolitica in the initial intestinal stage of
the infection (Pepe et al., 1995). The role of YadA in Y. pseudotuberculosis infection
remains unclear, however, as the yadA mutant is as virulent as the wild type Y.
pseudotuberculosis strain (Bölin and Wolf-Watz, 1984). In Y. pestis, YadA is silenced
as a result of a single nucleotide deletion in the yadA gene (Rosqvist et al., 1988;
Skurnik and Wolf-Watz, 1989). The Y. pestis lifestyle differs dramatically from that of
Y. enterocolitica and Y. pseudotuberculosis. The YadA required for adhesion to gut
tissue appears to be redundant for the plague bacterium and therefore is represented by
the pseudogene.
Expression of the yadA gene is thermodependent and under the control of the virF/lcrF
gene which encodes for a transcriptional activator driving YadA expression at 37°C
but not below 30°C (Lambert de Rouvroit et al., 1992; Skurnik and Toivanen, 1992).
YadA is a homotrimeric 200- to 240-kDa outer membrane protein with a monomer
size of about 44 kDa (Mack et al., 1994; Nummelin et al., 2004; Skurnik et al., 1984).
YadA belongs to the family of trimeric autotransporters and consists of an internal
passenger domain and a C-terminal translocation unit (Fig. 8) (Cotter et al., 2005;
Hoiczyk et al., 2000; Roggenkamp et al., 2003; Skurnik and Wolf-Watz, 1989; Surana
et al., 2004). The YadA passenger domain consists of N-terminal head, neck, and
coiled-coil stalk domains and is followed by a C-terminal translocation and membrane-
anchoring unit (Hoiczyk et al., 2000). A detailed description of the YadA structural
units is given below for the Y. enterocolitica serotype O:3. The membrane anchor
represents a 12-stranded -barrel closed by a stalk segment of four heptamers (residues
368-395) (Koretke et al., 2006). The left-handed coiled-coil segment continues into a
right-handed coiled-coil (residues 214-367) stalk built of 15-residue repeats
(pentadecads) (Hoiczyk et al., 2000). The number of these degenerate repeats is strain-
specific. The right-handed part of the stalk of Y. enterocolitica serotype O:3 has been
predicted to consist of one exceptional 19-residue unit following the left-handed
segment, and nine pentadecads (Koretke et al., 2006). The right-handed part of the
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stalk is connected to the neck region (residues 192-213) that comprises a safety pin-
like element of each monomer (Nummelin et al., 2004) and makes the transition from
the rod-like stalk to the globular head. The head domain, about 5 nm long, is a tight
cylindrical trimeric structure formed by left-handed -rolls (Nummelin et al., 2004).
The export of autotransporters through the inner membrane, involving the Sec
machinery, is initiated by the signal peptide. Once through the inner membrane, the
signal sequence is cleaved off, and the translocation domain is inserted into the outer
membrane, forming a -barrel structure (Cotter et al., 2005). This structure constitutes
a pore in the outer membrane through which the YadA passenger domain extrudes.
The exact mechanism by which the passenger domain is translocated through the pore
remains, however, poorly understood. Once all three YadA subunits have been
translocated, the protein folds completely and achieves its native conformation. As
YadA has no cysteines (Skurnik and Wolf-Watz, 1989), its trimerization depends
strongly on ionic or hydrophobic interaction, or both, between the polypeptide chains.
Head
Neck
Stalk
Anchor
Autoagglutination
Binding to: collagen
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epithelial cells
complement resistance
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oligomerization
complement resistance
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Figure 8. Schematic representation of YadA domains and their functions (modified from
Koretke et al., 2006); TU, translocation unit.
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YadA appears on bacterial surface within minutes after a temperature-shift to 37°C
(Bölin et al., 1982). Because YadA molecules on neighboring bacteria interact with
each other in a zipper-like fashion, involving the head and neck domains, bacteria tend
to autoagglutinate (Balligand et al., 1985; Hoiczyk et al., 2000).
YadA is unusual in a number of its functions (Table 7). It binds to mucin (Paerregaard
et al., 1991a) to facilitate bacterial colonization of the intestine, and it mediates the
binding of bacteria to 1-integrins on the host cells via a fibronectin bridge (Eitel and
Dersch, 2002). The latter activity, specific for Y. pseudotuberculosis YadA, which is
bearing a unique N-terminal sequence (Heise and Dersch, 2006), may stimulate
phagocytic activity of the M cells to transport Yersiniae across the intestinal
epithelium. Y. enterocolitica YadA binds fibronectin (Schulze-Koops et al., 1993;
Tertti et al., 1992) but does not mediate invasion of human epithelial cells (Heesemann
and Grüter, 1987; Schmid et al., 2004). In addition to fibronectin, YadA also binds to
other extracellular matrix proteins such as collagen types I, II, III, IV, V, and XI
(Emödy et al., 1989; Schulze-Koops et al., 1992), and laminin types 1 and 2 (Flügel et
al., 1994).
YadA also mediates adherence to cultured human epithelial cells (Bliska et al., 1993;
Heesemann and Grüter, 1987), rabbit intestinal tissue (Paerregaard et al., 1991b),
guinea pig erythrocytes (Kapperud and Lassen, 1983; Kapperud et al., 1985), human
intestinal submucosa (Skurnik et al., 1994), and phagocytic cells such as neutrophils
(Roggenkamp et al., 1996) and macrophages (Mota et al., 2005). YadA binding to
macrophages has been shown to anchor the bacteria so that the type III secretion
needle can reach the host cell membrane, and the effector proteins can be translocated
to the cytoplasm of the host cell (Mota et al., 2005).
1.6.4.1.2 YadA-mediated serum resistance
One of the multiple functions of YadA is bactericidal serum resistance. This functional
characteristic is shared by several members of the oligomeric coiled-coil adhesin (Oca)
family (Table 8). YadA protects bacteria against bactericidal action of serum as
transposon insertion yadA mutants prove susceptible to human serum, and, in addition,
YadA expressed in E. coli K12 confers serum resistance upon this normally serum-
sensitive bacterium (Balligand et al., 1985; Martinez, 1989). Attempts to identify the
mechanism of YadA-mediated complement resistance implicated YadA in the
REVIEW OF THE LITERATURE
- 39 -
inhibition of complement activation at both C3b and C9 levels (China et al., 1993; Pilz
et al., 1992). Bacteria expressing YadA were also shown more rapidly degrade
surface-bound C3b to iC3b, and accordingly, display higher resistance to opsonin-
mediated phagocytosis (Grosdent et al., 2002; Pilz et al., 1992). It has been proposed
that YadA may silence the complement activation and reduce C3b-opsonization by
coating the bacterial surface with FH (China et al., 1993; Roggenkamp et al., 1996).
No direct binding of FH to YadA, however, has been demonstrated.
Protein Organism Serum resistance
mechanism
Reference
Omp100
(outer membrane protein 100)
Actinobacillus
actinomyctemcomitans
FH binding Asakawa et al.,
2003
DsrA
(ducreyi serum resistance A)
Haemophilus ducreyi C4bp binding
vitronectin binding
Abdullah et al.,
2005
UspA1 and UspA2
(ubiquitous surface protein A)
M. catarrhalis C4bp binding
vitronectin binding
Nordström et
al., 2004; Attia
et al., 2006
Eib
(E. coli Ig binding)
E. coli unknown Sandt and Hill,
2000
Hsf
(Haemophilus surface fibrils)
Haemophilus
influenzae
vitronectin binding Hallström et al.,
2006
A study aimed at identification of YadA segments contributing to serum resistance
argued that this function could not be ascribed to a single YadA domain (Roggenkamp
et al., 2003). Both the head domain and the neck region appeared to be required for the
YadA-mediated complement resistance (Roggenkamp et al., 2003). It has been
proposed, however, that regions within the stalk and the translocation domain function
as serum-resistance determinants (Ackermann et al., 2008; Roggenkamp et al., 2003).
Table 8. Members of the YadA family conferring serum resistance.
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1.6.4.2 Ail
Ail is a 17-kDa outer membrane protein encoded by the chromosomally located ail
gene (Miller and Falkow, 1988; Miller et al., 1990). The presence of this gene has
been associated exclusively with the pathogenic Y. enterocolitica species (Miller et al.,
1989). Transcription of the ail gene is regulated by the temperature and the growth
phase of the bacteria. In log-phase bacteria, the ail transcript is detectable at 22°C,
28°C, and 37°C, whereas in the stationary-phase bacteria, Ail is expressed exclusively
at 37°C (Pierson and Falkow, 1993). In addition, Ail expression is reduced when
bacteria grow under limited oxygen conditions (Pederson and Pierson, 1995).
Ail belongs to a family of proteins predicted to form eight outer membrane-spanning
amphipatic -strands and four short extracellular loops (Fig. 9) (Beer and Miller, 1992;
Stoorvogel et al., 1991; Vogt and Schulz, 1999). These loops appear to be masked to
some extent by the full-length LPS (Pierson, 1994).
Ail mediates attachment to, and subsequent invasion of yersinia into eukaryotic cells
(Miller and Falkow, 1988) but the exact mechanism of Ail-mediated invasion is
unknown. The role for Ail in vivo also remains to be determined, since ail-defective
bacteria cross the gastrointestinal epithelium in a similar fashion as do the wild type
bacteria (Wachtel and Miller, 1995). Nevertheless, Ail is indeed produced by bacteria
in vivo during the first two days of infection (Wachtel and Miller, 1995).
1.6.4.2.1 Ail-mediated serum resistance
The family of outer membrane proteins structurally related to Ail includes E. coli and
Enterobacter cloacae OmpX, and Salmonella typhimurium PagC and Rck (Beer and
Miller, 1992; Heffernan et al., 1992; Mecsas et al., 1995; Pulkkinen and Miller, 1991;
Stoorvogel et al., 1991). Only Rck, however, shares functional homology with Ail;
namely its resistance to complement (Heffernan et al., 1994). Ail has been implicated
in resistance to complement-mediated killing based on the following observations: (i)
pathogenic Y. enterocolitica ail-defective mutant bacteria became sensitive to serum
killing and the serum-resistance phenotype of the strain was restored by
complementation by a wild-type copy of the ail gene, (ii) introducing ail into
laboratory E. coli strains and non-pathogenic strains of Y. enterocolitica resulted in
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increased resistance to killing by human serum (Bliska and Falkow, 1992; Pierson and
Falkow, 1993). The serum resistance-conferring regions of Y. enterocolitica serotype
O:8 Ail have been mapped to the C-terminal end of loop 2 and the N-terminal end of
loop 3 (Miller et al., 2001).
1.6.4.3 LPS
LPS is the major component of the outer membrane of Y. enterocolitica; it has three
main structural components: lipid A, the core (inner and outer), and O-ag. Unlike in
many other Gram-negative bacteria, in Y. enterocolitica serotypes O:3 and O:9, the O-
ag and the OC are linked to the inner core (IC), forming a branched structure on the
bacterial surface (Fig. 10) (Skurnik et al., 1995; Skurnik and Bengoechea, 2003).
1.6.4.3.1 O-antigen
O-ags of Y. enterocolitica serotypes O:3 and O:9 are homopolymers of 6-deoxy-L-
altrose and N-formylperosamine, respectively (Caroff et al., 1984; Hoffman et al.,
1980).
Figure 9. Schematic representation of the E. coli OmpX structure (modified from
Fernandez et al., 2002); loops 1-4 (L1-4).
REVIEW OF THE LITERATURE
- 42 -
Homopolymeric O-ags are fully synthesized at the cytoplasmic face of the inner
membrane, on the membrane-bound carrier undecaprenyl phosphate (Und-P). Und-P
accepts the first sugar moiety from nucleotide diphosphate (NDP)-activated sugar
precursors that function as sugar donors. This reaction and the sequential transfer of
sugar moieties to the growing polysaccharide polymer is carried out by specific
glycosyltransferases. The full-length O-ag polymer is translocated to the periplasm via
ATP-driven transporter system formed of the members of ABC transporter family.
Subsequently the polymer is ligated by the O-ag ligase to pre-formed lipid A-core and
translocated to the outer membrane (Raetz and Whitfield, 2002).
The Y. enterocolitica serotype O:3 O-ag gene cluster is composed of two operons (Fig.
11), both  essential for O-ag synthesis and both transcribed from tandem promoters
(Al-Hendy et al., 1991a, 1992; Zhang et al., 1993). These operons are likely to encode:
(i) enzymes involved in the biosynthesis of the NDP-activated sugar precursor, dTDP-
6-deoxy-L-altrose (wbbS, wbbV and wbbW), (ii) two glycosyltransferases to initiate the
O-ag synthesis and to extend the homopolymer (wbbT and wbbU), and (iii) ABC
transporter system (wzt and wzm) (Skurnik, 1999; Zhang et al., 1993). The genomic
location of the O-ag gene cluster is unknown. The organization and characterization of
the O-ag gene cluster of serotype O:9 is presented in Study II.
O-antigen
Outer core
Inner core
Lipid A
Figure 10. A schematic drawing of LPS of Y. enterocolitica serotype O:3 (modified from
Skurnik et al., 1995).
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O-ag expression is regulated by the temperature and the growth phase. Below 30°C, O-
ag expression by bacteria in the stationary phase (or near the start of the stationary
phase of growth) is maximal.  Bacteria in the exponential phase, however, express O-
ag constitutively and regardless of the growth temperature (Lahtinen et al., 2003).
Y. enterocolitica serotype O:3 O-ag serves as a receptor for bacteriophage YeO3-12
(Al-Hendy  et al., 1991a). In addition, it plays a role in the virulence of Y .
enterocolitica and appears to be required for effective colonization of host tissues
during the very first hours of infection (Al-Hendy et al., 1992; Skurnik et al., 1999).
1.6.4.3.2 Outer core
OC gene clusters of Y. enterocolitica serotypes O:3 and O:9 are very closely related
and are located between the hemH and gsk genes. Interestingly, this locus in Yersinia is
usually occupied by heteropolymeric O-ag gene clusters (Skurnik et al., 1995;
Skurnik and Bengoechea, 2003). OC of Y. enterocolitica serotype O:3 is, however,
thought to be an ancestral O-unit which serves as a receptor for bacteriophage R1-37
and enterocoliticin (Skurnik et al., 1995; Strauch et al., 2003).
Hexasaccharide OC of Y. enterocolitica serotype O:3 forms a branch consisting of two
glucoses, two N-acetyl-D-galactosamines, galactose, and 2-acetamido-2,6-dideoxy-D-
xylo-4-hexulose (Duda, 2007; Skurnik, 1999). The latter sugar links the OC to the IC.
OC biosynthesis begins at the cytoplasmic face of the inner membrane on the Und-P.
The transfer of sugar residues—from NDP-sugar precursors—to the growing
hexasaccharide is carried out by glycosyltransferases. Completed hexasaccharide is
flipped to the periplasmic space, and subsequently ligated to the lipidA-inner core
structure (Skurnik, 1999).
wbbS wbbT wbbU wzm wzt wbbV wbbW wbbX
P3,4P1,2
Figure 11. O-ag gene cluster of Y. enterocolitica serotype O:3, schematic drawing
(modified from Skurnik and Bengoechea, 2003).  Individual genes are drawn as arrows but
not to scale. Colour of each arrow indicates gene function; grey, biosynthetic enzyme;
white, glycosyltransferase; and black, polysaccharide transporter. P1,2 and P3, 4, tandem
promoters.
REVIEW OF THE LITERATURE
- 44 -
The Y. enterocolitica serotype O:3 OC gene cluster consists of nine genes presumably
encoding: (i) enzymes involved in the biosynthesis of the NDP-activated sugar
precursors (wbcP and gne), (ii) six glycosyltransferases (wbcK, wbcL, wbcM, wbcN,
wbcO, and wbcQ), and (iii) a flippase (wzx) (Fig. 12) (Skurnik et al., 1995; Skurnik
and Bengoechea, 2003).
OC is required for the full virulence of Y. enterocolitica serotype O:3, for colonization
of the deeper organs, and for prolonged persistence of the bacteria in the Peyer’s
patches (Skurnik et al., 1999). OC provides also resistance against antimicrobial
peptides and that suggests its role in resistance to innate host defense mechanisms
(Skurnik et al., 1999).
1.6.4.3.3 LPS and serum resistance
Although a role for O-ag of Y. enterocolitica in the inhibition of AP activation is
suggested based on the studies using the guinea pig serum, studies using human serum
do not provide evidence for involvement of O-ag and OC in serum resistance (Skurnik
et al., 1999; Wachter and Brade, 1989).
Figure 12. OC gene cluster of Y. enterocolitica serotype O:3, schematic drawing (modified
from Skurnik and Bengoechea, 2003). Individual genes are drawn as arrows but not to scale.
The color of each arrow indicates gene function; gray, biosynthetic enzyme; white,
glycosyltransferase; and black, flippase. Dashed-line arrows represent genes flanking the
OC cluster.
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2. AIMS OF THE STUDY
This thesis work was undertaken to increase our understanding of molecular details of
the interactions between the Y. enterocolitica surface factors and serum complement
components. The specific aims of this study were:
1. to determine the role of Y. enterocolitica surface factors YadA, Ail, and LPS in
bacterial resistance against complement-mediated killing.
2. to investigate whether Y. enterocolitica utilizes the AP inhibitor FH and the CP
inhibitor C4bp, to resist the complement system.
3. to identify and map the regions of the bacterial complement resistance factors
interacting with the complement regulators.
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3. MATERIALS AND METHODS
The materials and methods of this study are listed below, with detailed descriptions in
the original publications, which are here referred to by Roman numerals.
Bacterial strains     Description
Source or
reference
Used
in
Y. enterocolitica O:3
6471/76 (YeO3) Serotype O:3, patient isolate, wild type Skurnik, 1984 I, III,
V
31761 Serotype O:3, fecal isolate HUSLAB, Helsinki,
Finland
V
49008 Serotype O:3, blood isolate HUSLAB, Helsinki,
Finland
V
49491 Serotype O:3, blood isolate HUSLAB, Helsinki,
Finland
V
YeO3-Ail
ail::Km-GenBlock, Kmr This study I, III
YeO3-Ail-R Spontaneous rough derivative of YeO3-Ail,
Kmr
This study I, III
YeO3-Ail-OCR Spontaneous OC mutant derivative of YeO3-
Ail-R, Kmr
This study I, III
YeO3-trs-11
(wzx-wbcL)::Km-GenBlock, Kmr, derivative
of YeO3
Skurnik et al., 1995 I, III
YeO3-trs-11R Spontaneous rough derivative of YeO3-trs11,
Kmr
Skurnik et al., 1995 I, III
YeO3-OC
(wzx-wbcQ), derivative of YeO3 This study I, III
YeO3-OCR  Spontaneous rough derivative of YeO3-OC This study I, III
YeO3-Ail-OC
ail::Km-GenBlock, Kmr, derivative of YeO3-
OC
This study I, III
YeO3-R2 Spontaneous rough derivative of YeO3 Al-Hendy et al., 1992 I, III
YeO3-O28
yadA::Km-GenBlock, Kmr, derivative of
YeO3
This study I, III,
V
YeO3-O28-R Spontaneous rough derivative of YeO3-O28,
Kmr
This study I, III,
V
YeO3-O28-OCR Spontaneous OC mutant derivative of YeO3-
O28-R1, Kmr
This study I, V
YeO3-O28-OC
(wzx-wbcQ) derivative of YeO3-O28, Kmr This study I, III,
V
6471/76-c
(YeO3-c)
Virulence plasmid cured derivative of YeO3 Skurnik, 1984 I, III,
IV,
V
YeO3-R1 Spontaneous rough derivative of YeO3-c Al-Hendy et al., 1992 I, III,
V
Table 9. Bacterial strains used in this study
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YeO3-c-OC
(wzx-wbcQ) derivative of YeO3-c This study I, III,
V
YeO3-c-OCR Spontaneous rough derivative of YeO3-c-OC This study I, III,
V
YeO3-c-trs8
(wzx-wbcL)::Km-GenBlock, Kmr, derivative
of YeO3-c
Skurnik et al., 1995 I, III
YeO3-c-trs8R Spontaneous rough derivative of YeO3-c-trs8,
Kmr
Skurnik et al., 1995 I, III
YeO3-c-Ail
ail::Km-GenBlock, Kmr, derivative of
YeO3-c
This study I, III,
IV,
V
YeO3-c-Ail-OC Spontaneous OC mutant derivative of
YeO3-c-Ail, Kmr
This study I, III,
V
YeO3-c-Ail-R Spontaneous rough derivative of YeO3-c-Ail,
Kmr
This study I, III,
V
YeO3-c-Ail-OCR Spontaneous OC mutant derivative of
YeO3-c-Ail-R, Kmr
This study I, III,
IV,
V
Y. enterocolitica O:8
8081 Serotype O:8, wild type Portnoy et al., 1981 V
YeO8-116
yadA::Km-GenBlock, derivative of 8081,
Kmr
This work V
90937
(ATCC 23715)
Serotype O:8, quality assessment strain,
Labquality, Helsinki, Finland, pYV-negative
HUSLAB, Helsinki,
Finland
V
Y. enterocolitica O:9
90936 Serotype O:9, quality assessment strain HUSLAB, Helsinki,
Finland
V
34884 Serotype O:9, blood isolate HUSLAB, Helsinki,
Finland
V
Ruokola/71 Patient isolate Skurnik, 1984 II
Ruokola/71-c Spontaneous virulence plasmid cured
derivative of Ruokola/71
Skurnik, 1984 II
YeO9-R1
per::Km-GenBlock, rough (O-ag negative),
Kmr derivative of Ruokola/71
This work II
YeO9-OC
(wzx-wbcL)::Km-GenBlock, OC negative,
Kmr derivative of Ruokola/71
This work II
YeO9-OCP Phage R1-37 resistant spontaneous OC-low-
expressing derivative of Ruokola/71
This work II
E. coli
C600 thi thr leuB tonA lacY supE Appleyard, 1954 I, V
DH10B F- mcrA (mrr-hsd RMS-mcrBC),
80lacZM15 lacX74, deoR, recA1 endA1
ara139(ara, leu)7697 galU, galK - rpsL
nupG - tonA
Life Technologies IV
HB101/pRK2013 Triparental conjugation helper strain, Kmr Figurski and Helinski,
1979
I, IV,
V
JM103 Sequencing host strain Messing et al., 1981 III,
V
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JM109 reaA1 lac-pro endA1 gyrA96 thi-1 hsdR17
supE44 relA1 F’ traD36 proAB+ lacI
q
ZM15
Yanisch-Perron et al.,
1985
IV,
V
S17-1 recA derivative of E. coli 294 (F- thi pro hsdR)
carrying a modified derivative of IncP
plasmid pRP4 (Aps Tcs Kms) integrated in the
chromosome, Tpr
Simon et al., 1983 V
S17-1pir thi pro hsdR- hsdM+ recA::RP4-2-Tc::Mu-
Km::Tn7, Strr (pir)
De Lorenzo and
Timmis, 1994
I, II
SY327pir (lac pro) argE (Am) rif nalA recA56 (pir) Miller and Mekalanos,
1988
I, II
MATERIALS AND METHODS
- 49 -
Plasmids     Description
Source or
reference
Used
in
pAil-8 A pBR322 clone carrying a 8-kb insert of YeO3-c
containing the ail gene, Ampr
This study I
pAil-8.1 PvuII deletion derivative of pAil-8, Ampr This study I
pAil-8.2 EcoRV-NruI deletion derivative of pAil-8.1, Ampr This study I
pBR322 Cloning vector, Ampr Tetr Bolivar et
al., 1977
I
pJM703.1 Suicide vector, contains R6K origin of replication and
RP4 Mob region; must be replicated in (pir) hosts,
Ampr
Miller and
Mekalanos,
1988
I
pL2.1 pBR322 with the Ptac promoter, Amp
r Viitanen et
al., 1990
III,
V
pRV1 Suicide vector, derivative of pJM703.1, Clmr Skurnik et
al., 1995
I
pRV7 A pBR322 clone carrying a 12.4-kb insert of YeO3-c
covering the OC gene cluster, Ampr
Skurnik et
al., 1995
I
pRV19-GB Suicide vector to inactivate OC gene cluster, (wzx-
wbcL)::Km-GenBlock, Clmr Kmr
Skurnik et
al., 1995
II
pRV37 Intermediate to construct OC deletion suicide vector;
pBR322 carries a HindIII fragment of pRV7 from
which the OC gene cluster is deleted by PCR, Ampr
This study I
pRV38 2-kb HindIII fragment of pRV37 cloned into pRV1
(O:3 OC gene cluster suicide vector), Clmr
This study I
pRV42 Suicide vector constructed to inactivate the ail gene;
Km-GenBlock inserted between ail flanking fragments
and cloned into pRV1, Kmr, Clmr
This study I
pTM100 Mobilizable vector, pACYC184-oriT of RK2, Clmr Michiels and
Cornelis,
1991
I,
IV,
V
pTM100-ail ail gene cloned in a 1711 bp PCR fragment
(nucleotides 1490-3201**) into EcoRV site of
pTM100, Clmr
This study IV,
V
pTM100-ail1 bp 2459-2461 CAC substituted for GCA in
pTM100-ail; expresses Ail with His65Ala
substitution (loop2)
This study IV
pTM100-ail2 bp 2465-2470 GATCTT substituted for
GGAGGT in pTM100-ail; expresses very low
levels of Ail with Asp67Gly and Leu68Gly
substitutions (loop2)
This study IV
pTM100-ail3 bp 2465-2470 GATCTT substituted for
GCACGA in pTM100-ail; expresses very low
levels of Ail with Asp67Ala and Leu68Arg
substitutions (loop2)
This study IV
pTM100-ail4 bp 2564-2566 TCA substituted for GAT in
pTM100-ail; expresses Ail with Ser100
substituted for Asp (loop3)
This study IV
pUC-4K Origin of the Km-GenBlock cassette, Ampr, Kmr Pharmacia I, V
Table 10. Plasmids used in this study
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pYMS3221x yadA cloned as 4.4-kb XbaI-PvuI fragment between
EcoRV-XbaI sites of pTM100
This study V
pYMS3223 Km-GenBlock inserted in the ClaI site of pYMS3221x This study V
pYMS 4450 promoterless yadA cloned into pL2.1; Ampr Skurnik et
al., 1994
III,
V
pYMS 4505 yadA gene of YeO3 cloned as a 1735 bp PCR fragment
(nucleotides 478-2213*) into BamHI site of pTM100;
Clmr
El Tahir et
al., 2000
I
pYMS4505:NECK bp 1194-1271 deletion of the yadA gene in pYMS 4505;
expresses YadA with 26 aa deletion (aa 193-218)
This study IV
pYMS4505:A bp 1257-1301 deletion of the yadA gene in pYMS 4505;
expresses YadA with 15 aa deletion (aa 214-228)
This study IV
pYMS4505:S bp 1281-1325 deletion of the yadA gene in pYMS 4505;
expresses YadA with 15 aa deletion (aa 222-236)
This study IV
pYMS4505:#1 bp 1311-1355 deletion of the yadA gene in pYMS 4505;
expresses YadA with 16 aa deletion (aa 231-246)
This study IV
pYMS4505:B bp 1347-1391 deletion of the yadA gene in pYMS 4505;
expresses YadA with 15 aa deletion (aa 244-258)
This study IV
pYMS4505:#2 bp 1356-1403 deletion of the yadA gene in pYMS 4505;
expresses YadA with 16 aa deletion (aa 247-262)
This study IV
pYMS4505:C bp 1359-1403 deletion of the yadA gene in pYMS
4505; does not express YadA due to a frame shift
mutation introduced during the construction
This study IV
pYMS4505:D bp 1371-1415 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
252-266)
This study IV
pYMS4505:E bp 1383-1427 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
256-270)
This study IV
pYMS4505:#3+6 bp 1398-1448 deletion of the yadA gene in pYMS
4505; expresses YadA with 17 aa deletion (aa
261-277)
This study IV
pYMS4505:F bp 1392-1436 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
259-273)
This study IV
pYMS4505:#3 bp 1404-1448 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
263-277)
This study IV
pYMS4505:H bp 1416-1460 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
267-281)
This study IV
pYMS4505:I bp 1428-1472 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
271-285)
This study IV
pYMS4505:#4 bp 1449-1493 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
278-292)
This study IV
pYMS4505:J bp 1482-1571 deletion of the yadA gene in pYMS
4505; expresses YadA with 30 aa deletion (aa
289-318)
This study IV
pYMS4505:#5 bp 1494-1538 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
293-307)
This study IV
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pYMS4505:#5-6 bp 1494-1583 deletion of the yadA gene in pYMS
4505; expresses YadA with 30 aa deletion (aa
293-322)
This study IV
pYMS4505:K bp 1506-1595 deletion of the yadA gene in pYMS 4505;
expresses YadA with 30 aa deletion (aa 297-326)
This study IV
pYMS4505:L bp 1518-1607 deletion of the yadA gene in pYMS 4505;
expresses YadA with 30 aa deletion (aa 301-330)
This study IV
pYMS4505:#6 bp 1539-1583 deletion of the yadA gene in pYMS 4505;
expresses YadA with 15 aa deletion (aa 308-322)
This study IV
pYMS4505:#6+3 bp 1539-1586 deletion of the yadA gene in pYMS 4505;
expresses YadA with 16 aa deletion (aa 308-323)
This study IV
pYMS4505:M bp 1572-1616 deletion of the yadA gene in pYMS 4505;
expresses YadA with 15 aa deletion (aa 319-333)
This study IV
pYMS4505:#7-9 bp 1584-1706 deletion of the yadA gene in pYMS
4505; expresses YadA with 41 aa deletion (aa
323-363)
This study IV
pYMS4505:N bp 1617-1661 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
334-348)
This study IV
pYMS4505:O bp 1662-1706 deletion of the yadA gene in pYMS
4505; expresses YadA with 15 aa deletion (aa
349-363)
This study IV
pYMS4505:P bp 1707-1727 deletion of the yadA gene in pYMS
4505; expresses YadA with 7 aa deletion (aa 364-
370)
This study IV
pYMS4505:1-3 bp 1707-1772 deletion of the yadA gene in pYMS
4505; does not express surface-located YadA, 22
aa deletion (aa 364-385)
This study IV
pYMS4505:Q bp 1728-1748 deletion of the yadA gene in pYMS
4505; expresses YadA with 7 aa deletion (aa 371-
377)
This study IV
pYMS4505:R bp 1749-1769 deletion of the yadA gene in pYMS
4505; expresses YadA with 7 aa deletion (aa 378-
384)
This study IV
pYMS 4506
yadA::Km-GenBlock derivative of pYMS4505; the
internal 1.3-kb NsiI fragment of yadA gene replaced
with Km-GenBlock; Clmr, Kmr
This study I
pYMS 4509 The yadA::Km-GenBlock fragment cloned into
EcoRI site of pJM703.1; Ampr, Kmr
This study I
pYMS 4515 Suicide vector to inactivate the yadA gene; the cat
gene of pTM100 cloned into the PstI site of
pYMS4509; Clmr, Kmr
This study I
pYV8081 Virulence plasmid of 8081 Portnoy et
al., 1981
V
* in all yadA mutants, nucleotide positions refer to the numbering of the 2551 bp sequence containing
the yadA-gene of Y. enterocolitica O:3 under Acc. no. X13882.
** in all ail mutants, nucleotide positions refer to the numbering of the 3865 bp sequence containing the
ail-gene of Y. enterocolitica O:3 under Acc. no. AJ605740
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Antibody name
or cat. no
    Description
Source or
reference
Used
in
Primary
antibodies
2A9 Mouse monoclonal antibody against YadA of
Y. enterocolitica O:3, epitope within aa 193-244
Skurnik et al., 1994 III,
IV
2G12 Mouse monoclonal antibody against YadA of
Y. enterocolitica O:3, epitope within aa 193-214
Skurnik et al., 1994 III,
IV
3G12 Mouse monoclonal antibody against YadA of
Y. enterocolitica O:3, epitope within aa 236-263
Skurnik et al., 1994 I,
III,
IV
Tom A6 Mouse monoclonal antibody against O-ag of
Y. enterocolitica O:3
Pekkola-Heino et
al., 1987
I
2B5 Mouse monoclonal antibody against OC of
Y. enterocolitica O:3
Pekkola-Heino et
al., 1987
I
755 Mouse monoclonal antibody against -chain of
human C3
Vogel et al., 1997 I
C2456 Mouse monoclonal antibody against collagen type I SIGMA IV
A0062 Rabbit antiserum against human C3c DAKO III
A0063 Rabbit antiserum against human C3d DAKO III
A312 Goat antiserum against human FH QUIDEL III,
IV
PC026 Sheep antiserum against human C4bp The Binding Site,
Birmingham, UK
V
A0065 Rabbit antiserum against human C4c DAKO V
Secondary
antibodies
P0260 Peroxidase-conjugated rabbit anti-mouse
immunoglobulins
DAKO I,
IV
P217 Peroxidase-conjugated swine anti-rabbit
immunoglobulins
DAKO III,
IV,
V
P449 Peroxidase-conjugated rabbit anti-goat
immunoglobulins
DAKO III,
IV
713-035-147 Peroxidase-conjugated donkey anti-sheep
immunoglobulins
Jackson
ImmunoResearch
Laboratories
V
Table 11. Antibodies used in this study
MATERIALS AND METHODS
- 53 -
Bacteriophages
and bacteriocins
    Description
Source or
reference
Used
in
Bacteriophages
YeO3-12 O-antigen specific phage of Y. enterocolitica O:3 Al-Hendy et al.,
1991a
I
R1-37 Outer core specific phage of Y. enterocolitica O:3 Skurnik et al.,
1995
I,
II,
III
R8-01 Infects O-ag and OC-negative Y. enterocolitica O:3
bacteria
This study III
Enterocoliticin Outer core-specific bacteriocin Strauch et al.,
2001, 2003
I
Purified protein     Description
Source or
reference
Used
in
FH Human Calbiochem
(341274)
III,
IV
FI Human Calbiochem
(341280)
III,
IV,
V
Collagen type I Human SIGMA
(C7774)
IV
C3b Human; generated from C3 by factor B, factor D in
the presence of Mg2+
This study and
Koistinen et al.,
1989
III,
IV
C4b Human Calbiochem
(204897)
V
SCR 1-5 Human, recombinant FH construct produced in
the baculovirus expression system
This study and
Kühn and Zipfel,
1995
III,
IV
SCR 1-6 Human, recombinant FH construct produced in
the baculovirus expression system
This study and
Kühn and Zipfel,
1995
III,
IV
SCR 1-7 Human, recombinant FH construct produced in
the baculovirus expression system
This study and
Kühn and Zipfel,
1995
III,
IV
SCR 8-11 Human, recombinant FH construct produced in
the baculovirus expression system
This study and
Kühn and Zipfel,
1995
III,
IV
SCR 11-15 Human, recombinant FH construct produced in
the baculovirus expression system
This study and
Kühn and Zipfel,
1995
III,
IV
SCR 8-20 Human, recombinant FH construct produced in
the baculovirus expression system
This study and
Kühn and Zipfel,
1995
III,
IV
Table 12. Bacteriophages and bacteriocins used in this study
Table 13. Purified proteins used in this study
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Methods
Used
in
Site-directed mutagenesis I, IV
PCR I, II, IV
Cycloserine enrichment I
Cloning I, IV
Extraction of genomic or plasmid DNA or both I, II, IV, V
Screening of recombinant plasmids by size IV
Conjugation I, II, IV, V
Preparation of electrocompetent cells and electroporation I, IV, V
Construction of suicide vectors to eliminate the ail and yadA genes I
Isolation of spontaneous mutants using bacteriophages I, II
DOC-PAGE and silver staining I, II
Collagen affinity blotting IV
Tx-114 or -octylglucoside isolation of outer membrane proteins III, V
Bacterial outer membrane preparation I
Lipopolysaccharide isolation I, II
Radiolabeling of proteins using Iodine (125I) III, V
Human serum pool preparation I, II, III, IV, V
Enzyme-linked immunosorbent assay III
SDS-PAGE and Immunoblotting I, III, IV, V
Cofactor assay for C3b or C4b inactivation III, IV, V
Direct binding of radiolabeled proteins to Yersinia III, V
Serum bactericidal assay I, II, IV
Serum adsorption assay V
Binding of purified FH, FH recombinant constructs, or C4bp to bacteria III, IV, V
Ligand blotting analysis of FH or C4bp binding III, V
Bacteriophage sensitivity assay III
Modeling of the coiled-coil structure of the YadA mutants IV
Statistical methods II, III, IV
Table 14. Methods used in this study
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4. RESULTS AND DISCUSSION
4.1 Combined action of Y. enterocolitica outer membrane proteins and LPS
in resistance to complement-mediated lysis
The complement system contributes to innate immune responses by opsonizing and
killing microorganisms and by augmenting the inflammatory response. Escape from
innate defense mechanisms appears as a prominent evasion strategy of Y .
enterocolitica. By avoiding the activation of host innate defense mechanisms, Y.
enterocolitica, like many pathogenic bacteria, is able to resist the bactericidal activity
of complement. Several bacterial surface factors, studied individually, have been
implicated in the complement resistance. These include YadA, Ail, and LPS O-ag and
OC (Balligand et al., 1985; Bliska and Falkow, 1992; Martinez, 1989; Pierson and
Falkow, 1993; Skurnik et al., 1999; Wachter and Brade, 1989). Studies on the role of
LPS in serum resistance have, however, produced conflicting results (Skurnik et al.,
1999; Wachter and Brade, 1989).
To study the contribution of these four factors, we constructed 23 mutant strains of Y.
enterocolitica O:3 expressing different combinations of YadA, Ail, O-ag, and OC (I).
Survival of bacteria, in the exponential or stationary phase of growth, was tested by
incubating the bacteria in 70% normal human serum (NHS) (CP, LP, and AP
functional) or EGTA-Mg-treated serum (only AP functional). The reaction was
stopped after 0.5 or 2 hours’ incubation at 37°C, the samples were plated, and the
viable counts of the bacteria were determined (I). The results obtained correlated with
previous observations pointing to involvement of YadA and Ail in resistance to
CP/AP-mediated killing. In addition, the importance of the combination of the factors
in the outer membrane into providing optimal protection against serum killing, was
evident.
In general, bacteria growing exponentially were more complement-resistant than
bacteria grown to the stationary phase (Figs 4 and 5 in I). YadA, as the most potent
single-serum resistance factor, provided bacteria with long-term protection against
complement-mediated lysis (Fig. 2 in I). Ail, although crucial for bacterial defense
against serum killing, conferred short-term resistance and delayed the killing of
bacteria. The protective effect of Ail could, however, be seen when YadA-lacking
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bacteria were deprived of O-ag and OC (Fig. 3 in I). LPS is predicted to cover 	75%
of the bacterial surface (Raetz and Whitfield, 2002). It may thus sterically block small-
sized Ail in the outer membrane and, in consequence, interfere with the Ail-exerted
functions: serum resistance and, as shown earlier, attachment to/invasion of
mammalian cells (Pierson, 1994). Since also the binding of bacteriophages to their
receptors was blocked when these were located beneth the LPS “coat” [(Kawaoka et
al., 1983; Skurnik et al., 1995) and III], it is apparent that LPS can mask the bacterial
surface (Fig. 13).
Although remains unknown, how bacteria modulate LPS expression in vivo, in vitro O-
ag and OC expression is downregulated at 37°C (Al-Hendy et al., 1991a, b;
Muszynski, 2004). Thus, one can assume that bacteria, when needed, are able to
downregulate the expression of LPS in vivo to uncover factors crucial for certain steps
of an infection. This hypothesis appears to be quite applicable in the case of Y.
enterocolitica O:3 LPS, which provided no protection against complement-mediated
killing (Fig. 3 in I). Moreover, bacteria lacking either O-ag or OC displayed enhanced
resistance to CP/LP or AP killing, respectively. Interestingly, this dependence was
apparent only when the three factors YadA, Ail, and either O-ag or OC were expressed
(Fig. 2 in I). Thus, it appears that serum resistance factors, to be fully functional, must
be presented in the membrane in the correct context.
Figure 13. Schematic model of Y. enterocolitica surface illustrating serum resistance
factors.
YadA
Ail
O-ag
OC
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In contrast to serotype O:3, LPS appears to participate in serum resistance in serotype
O:9. The importance of long O-ag chains in resistance against complement lysis has
been demonstrated also for other pathogens (Burns and Hull, 1998; Grossman et al.,
1987; Joiner et al., 1986). In Y. enterocolitica O:9, however, LPS plays an accessory
role in serum resistance by strengthening the YadA-mediated protection; OC appears
to contribute to protection in the early exposure to serum, whereas O-ag contributes to
prolonged bacterial survival (Fig. 4 in II).
In general, within a population of the wild type bacteria of both serotypes there existed
serum-sensitive and serum-resistant fractions. One could speculate that the surviving
bacteria are hidden within aggregates typically formed by the YadA-expressing
bacteria. In addition, heterogeneity of the bacterial population may result from
differential expression of bacterial-surface factors. It is known that LPS molecules
isolated from any smooth Y. enterocolitica strain show an extensive variation in the
length of their O-ag chains. Moreover, some of these LPS molecules do not contain
attached O-ag chains (Skurnik, 2004). Thus, one could envision bacterial cells
equipped with fewer or shorter O-ag chains or both as being more resistant to
complement due to the greater exposure of YadA and Ail.
4.2 Y. enterocolitica and acquisition of complement regulators
Complement activation, being potentially deleterious for the host tissues, is tightly
regulated. Fluid-phase complement regulators are, however, often sequestered by
pathogens to prevent complement activation on their surfaces (Berggård et al., 1997;
Hellwage et al., 2001; Horstmann et al., 1988; Johnsson et al., 1996; Meri et al., 2002;
Nordström et al., 2004; Prasadarao et al., 2002; Ram et al., 1998b, 2001). We thus
aimed to verify whether binding of complement regulators such as FH and C4bp
would also be a mechanism of the complement resistance of Y. enterocolitica.
4.2.1 Acquisition of FH
First, we wanted to examine the mechanism by which Y. enterocolitica evades AP-
mediated killing. Although Y. enterocolitica binds FH from serum (China et al., 1993;
Roggenkamp et al., 1996), no direct binding of purified FH to bacteria has been
demonstrated (Roggenkamp et al., 2003). We thus aimed to re-examine whether Y.
enterocolitica acquires FH to prevent AP activation on its surface.
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Bacteria, incubated with human serum in the test tube or in microtiter wells were then
washed, and deposited serum FH was analyzed by immunoblotting or ELISA (Fig. 1 in
III). In both techniques, goat antiserum that recognizes human FH served for the
detection of bound FH.  As both methods confirmed the earlier observation that Y.
enterocolitica acquires serum FH (Fig. 1 in III), we wanted to examine whether Y.
enterocolitica involves other serum proteins to mediate the interaction with FH.
Bacteria were thus incubated with purified FH, washed, and subjected to SDS-PAGE
and immunoblotting. The analysis, using goat antiserum against human FH, revealed
that Y. enterocolitica O:3 bound purified FH directly (Fig. 2 in III). Since earlier
attempts to demonstrate a direct binding of purified/125I-labeled to Y. enterocolitica
had failed (Roggenkamp et al., 2003), we also re-assayed the binding experiment. We
did not succeed, however, in showing the 125I-FH binding to Y. enterocolitica, either
(III). We thus examined the effect of buffers used in the binding assay and found that
gelatin used to block non-specific binding was likely to inhibit the 125I-FH-Y.
enterocolitica interaction (III). Gelatin is a denatured form of collagen and greatly
inhibits YadA-mediated collagen binding (Emödy et al., 1989). One could thus suggest
that FH-Y. enterocolitica interaction, like that of collagen-Y. enterocolitica, involves
YadA and thus can be inhibited by gelatin.
The specificity of FH binding to Y. enterocolitica was further determined. Bacteria
were incubated with purified FH in the presence of bovine serum albumin (BSA). The
binding of FH was affected only by the highest BSA concentration tested, suggesting
that the binding of FH to Y. enterocolitica is specific (III).
We next aimed to study whether FH bound to the Y. enterocolitica surface remained in
a functional form, by testing the functional activity of Y. enterocolitica-bound FH in a
cofactor assay (Fig. 2 in III).  Bacteria pre-incubated with purified FH were incubated
further with FI and C3b. The degree of C3b cleavage was assayed by subjecting the
supernatants to SDS-PAGE/immunoblotting with a mixture of anti-C3c and anti-C3d
antibodies (Fig. 2 in III). Y. enterocolitica-bound FH acted as a cofactor for FI-
mediated cleavage of C3b, as the ’-chain of C3b became cleaved into 67 kDa, 43
kDa, and 41 kDa fragments. Thus, FH deposited on the Y. enterocolitica surface
retained its regulatory function.
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4.2.2 Acquisition of C4bp
As Y. enterocolitica resists the CP/LP-mediated killing (Fig. 2 in I), we wanted to
examine whether one mechanism underlying this resistance is acquisition of C4bp. A
serum adsorption assay was used to test whether Y. enterocolitica binds serum C4bp.
Bacteria were incubated in 5% heat-inactivated serum at 37°C; bacteria-bound serum
proteins were then eluted and subjected to SDS-PAGE/immunoblotting with sheep
antiserum against human C4bp (Fig. 3 in V). Because the immunoblotting results
revealed the presence of C4bp in the eluted fractions, we next studied whether Y.
enterocolitica binds C4bp independent of other serum proteins. 125I-labeled C4bp was
incubated with Y. enterocolitica serotypes O:3, O:8, and O:9. The bacteria that bound
radiolabeled C4bp were centrifuged through 20% sucrose, and the binding was
quantified with a gamma counter (Fig. 1 in V). All three Y. enterocolitica serotypes
directly bound C4bp.  The specificity of C4bp binding underwent further study in a
direct binding assay. Bacteria were incubated with 125I-C4bp in the presence of
unlabeled C4bp or BSA. The binding of 125I-C4bp was inhibited in a concentration-
dependent manner by unlabeled C4bp, whereas BSA did not affect 125I-C4bp binding.
In conclusion, we found that the binding of C4bp to Y. enterocolitica to be specific
(Fig. 7 in V).
To examine the functional activity of Y. enterocolitica-acquired C4bp, a cofactor assay
was performed. Bacteria pre-incubated with C4bp were subsequently washed and
incubated with C4b and FI. The C4bp-cofactor activity was verified by
immunodetection of C4b cleavage products in the collected supernatant by use of
immunoblotting with rabbit anti-human C4c antiserum (Fig. 2 in V).  The results
demonstrated that C4bp bound to Y. enterocolitica maintained its cofactor activity and
participated in C4b inactivation. In conclusion, we found C4bp to bind to Y.
enterocolitica in a way that does not interfere with its regulatory function.
RESULTS AND DISCUSSION
- 60 -  
4.3 Identification of FH and C4bp receptors on Y. enterocolitica
Given the Y. enterocolitica - FH and Y. enterocolitica - C4bp interaction, we wanted to
identify the potential receptors for these complement regulators on the surface of Y.
enterocolitica. To this end, we used a set of mutant strains of Y. enterocolitica O:3
expressing different combinations of YadA, Ail, O-ag, and OC, which had served to
identify those bacterial factors that confer serum resistance (I). The ability of the
mutant strains to bind serum FH or C4bp was tested by ELISA/immunoblotting or by
direct binding assay, respectively (Fig. 1 in III and Fig. 4 in V). In general, FH/C4bp
binding was dependent on the presence of those factors that confer complement
resistance, YadA and Ail. Importantly, the FH- and C4bp-binding pattern correlated
well with the serum sensitivities of the strains; the strains of intermediate and resistant
phenotype bound the regulators, whereas the sensitive ones failed to (I, III, V, Fig. 14).
In general, serum-sensitive strains bound negligible amounts of FH and C4bp (Fig.
14). Strains belonging to this group did not express YadA, the most potent single
serum resistance factor. It thus became evident that YadA expression is crucial for
C4bp/FH binding (Fig. 14). Interestingly, although several serum-sensitive strains
expressed Ail—shown earlier to confer serum resistance—Ail’s ability to bind
C4bp/FH was inhibited in the presence of O-ag or OC (YeO3-O28, YeO3-c, YeO3-
O28-OC, YeO3-c-OC, and YeO3-O28-R, Fig. 14). The distal parts of LPS lacked the
ability to bind either of the regulators, and in consequence did not protect the bacteria
against serum killing (YeO3-c-Ail, YeO3-c-Ail-OC, and YeO3-c-Ail-R).
All the strains expressing YadA were able to bind both FH and C4bp (Fig. 14). These
strains displayed intermediate (YeO3, YeO3-Ail, YeO3-Ail-OC, YeO3-Ail-OCR,
YeO3-Ail-R, and YeO3-OCR) or resistant phenotypes (YeO3-OC, YeO3-R2, YeO3-
trs11, and YeO3-trs11R). The only two strains that lacked YadA but were able to bind
FH and C4bp expressed Ail in the absence of both O-ag and OC (YeO3-c-OCR and
YeO3-c-trs8R, Fig. 14). Thus, Ail must be very well exposed in the outer membrane to
be able to bind complement regulators.
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Interestingly, the ability of YadA-expressing strains to bind FH was greatly enhanced
in the absence of O-ag (YeO3-R2, YeO3-trs11R, YeO3-OCR, YeO3-Ail-OCR, and
YeO3-AilR, Fig. 14). This suggests that the lack of O-ag might favor FH binding to
YadA by exposing its regions crucial for the binding. Lack of OC in the O-ag- YadA-
expressing strain did not greatly affect bacterial ability to bind FH (YeO3-OC). YeO3-
trs11, however, shown to express less O-ag than did YeO3-OC, bound more FH than
did the wild type (I and Fig. 1 in III).
Figure 14. Y. enterocolitica strains expressing different combinations of YadA, Ail, O-ag,
and OC. Serum resistance vs FH/C4bp binding phenotype: sensitive, <1% viable bacteria;
intermediate 1-20% viable bacteria; resistant, >20% viable bacteria after 120 min
incubation in NHS. Strains marked with an asterisk were tested only for the ability to bind
FH. See Fig. 13 for symbols.
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4.3.1 Characterization of YadA- Ail- mediated interactions with FH and C4bp
4.3.1.1 YadA and FH
These findings warranted further studies on the YadA- and Ail-mediated interactions
with FH and C4bp (III-V). YadA was initially identified as an FH receptor based on an
affinity-blotting experiment using whole serum as the FH source (China et al., 1993).
To show a direct interaction between FH and YadA, we re-assayed the affinity-
blotting experiment. YadA was extracted from E. coli with Triton X-114, and the
binding of purified FH to the extracted protein was tested in affinity blotting with goat
antiserum against anti-human FH. We observed the binding of purified FH to YadA,
thereby confirming that the interaction between YadA and FH is direct (Fig. 3 in III).
To assess the nature of the YadA-FH interaction, we incubated YadA-expressing
bacteria with purified FH in the presence of salt (50-650 mM) or heparin (0-1000
μg/ml). As salt did not greatly affect the binding of FH to YadA, the YadA-FH
interaction is likely to be hydrophobic in nature (Fig. 5 in III). Heparin had some effect
on FH-binding to YadA only at the highest concentrations used (Fig. 5 in III). This
suggests that the YadA-FH interaction does not depend primarily on SCR 7, SCR 13,
or SCR 20, which have been shown to be heparin-specific (Blackmore et al., 1996;
Blackmore et al., 1998b; Pangburn et al., 1991).
To characterize regions of FH involved in the YadA-FH interaction in more detail, we
incubated YadA-expressing bacteria with truncated recombinant constructs together
representing the entire FH. Binding of FH was detected by immunoblotting with goat
antiserum against human FH. All FH fragments bound to YadA-expressing bacteria,
suggesting that the interaction with YadA engages SCRs of the entire polypeptide
chain of FH (Fig. 15 and Fig. 4A in III). This finding confirmed the heparin inhibition
results. Since the SCR 1-5 construct contains the domain responsible for the regulatory
functions of FH, i.e., its cofactor and decay-accelerating activities (Gordon et al.,
1995; Kühn et al., 1995; Kühn and Zipfel, 1996), we next examined whether FH
bound to YadA remained functional. Despite the fact that YadA-FH interaction
involves SCRs 1-5, YadA-bound FH retained its regulatory function. Many pathogens
like B. burgdorferi, N. gonorrhoeae, and C. albicans target C-terminal SCRs of FH
(Hellwage et al., 2001; Meri et al., 2002; Ram et al., 1998b), S. pneumoniae targets its
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middle portion (Jarva et al., 2002), and S. pyogenes and B. burgdorferi target its N-
terminal region (Kotarsky et al., 1998; Kraiczy et al., 2004; Pandiripally et al., 2003).
Binding to the SCRs of the entire FH, however, has not been reported with any other
microbe and thus appears to be unique for YadA.
Since we showed that Y. enterocolitica-bound FH maintains its function, we wanted to
study whether YadA-expressing bacteria use FH to promote FI-mediated cleavage of
C3b (Fig. 2 in III). The cofactor assay results demonstrated that YadA-bound FH was
fully functional. Our C3b deposition experiments, however, did not support this
observation (Fig. 6 in I). The deposition findings not only failed to correlate with
resistance phenotypes of the strains, but also pointed to O-ag as a factor preventing the
deposition of C3b (Fig. 6 in I). Interestingly, no difference between the wild type and
the YadA-negative strains in 125I-C3 deposition from 10% EGTA-Mg serum was
observed by Pilz and co-workers either (Pilz et al., 1992). In contrast to this
observation, Tertti and co-workers reported that pYV+ bacteria displayed less serum
C3b deposited that did pYV- bacteria (Tertti et al., 1987). This difference between
strains only appeard, however, with NHS concentration no higher than 5% (Tertti et
al., 1987). China and co-workers showed, however, reduced C3b deposition, from
10% EGTA-Mg serum, on bacteria expressing YadA (China et al., 1993). As our data
showed no reduction in C3b deposition by YadA-positive strains, one could speculate
that the concentration of serum used in the assay was too high. We cannot at present
explain these discrepancies.
4.3.1.1.1 Mapping of YadA regions involved in FH-binding
As we found that O-ag blocks to some extent the binding of FH to YadA, we wanted to
examine whether O-ag blocks the binding of mAb to YadA in an analogous fashion
(III). We used the mAbs recognizing epitopes within the neck and the very N-terminal
Figure 15. Schematic representation of FH domains interacting with YadA of
Y. enterocolitica serotype O:3; lanes indicate recombinant fragments used.
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region of the YadA stalk (2A9, 3G12, and 2G12). The access of these mAbs to their
epitopes was not blocked, however, by the presence of O-ag. This suggested that YadA
regions interacting with FH are located closer to the bacterial outer membrane than are
the mAbs epitopes. The indication that regions of the YadA stalk may be involved in
FH binding and the fact that the YadA stalk, but not the head domain, mediates serum
resistance (Roggenkamp et al., 2003) warranted further studies on characterization of
YadA regions involved in both serum resistance and FH binding (IV). To this end, we
constructed 28 mutants (Fig. 16) having short internal deletions within the neck and
stalk of YadA, based on the proposed coiled-coil structure of the trimeric stalk
(Koretke et al., 2006). Plasmids carrying the mutated yadA gene were mobilized to the
plasmid-cured Y. enterocolitica O:3 host, YeO3-c. Expression of the trimerized and
surface-exposed YadA was detectable in all the mutants, except for the one carrying
deletion 364-385 (Fig. 1 in IV). This finding was consistent with the earlier finding
showing that this region, overlapping the junction between the right-handed and left-
handed parts of the stalk, is crucial for YadA translocation across the outer membrane
(Roggenkamp et al., 2003). Since all our stalk mutants bound collagen type I, the
deletions introduced did not affect the head and neck domains involved in collagen
binding (Fig. 1 in IV). Modeling analysis suggests that most deletions do not disturb
the structure of the stalk, whereas in certain mutant proteins the local periodicity and
thus degree of supercoiling are affected (IV).
The mutants were shown to be useful for the localization of epitopes for the three
mAbs specific for YadA: 3G12-15, 2A9, and 2G12. The epitopes were mapped to aa
236-263, 193-244, and 193-214 (Fig. 1 in IV) and appeared to be conformational
because mapping attempts using overlapping 16-mer YadA peptides had failed (El
Tahir et al., 2000).
The constructed mutants were tested for their ability to bind serum FH (ELISA and
immunoblotting using goat antiserum against human FH for detection), and their
serum sensitivities were determined in the serum bactericidal assay. One of the
constructed YadA mutants that did not express YadA due to an out-of-frame deletion
within the stalk-coding region, served as a control in all the experiments.
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In general, serum-resistant YadA deletion mutants bound FH (Fig. 3 in IV). However,
none of the constructed mutants, even those expressing YadA with broken periodicity,
was completely devoid of FH binding activity. This suggests that there exists no single
site on the YadA stalk that binds FH. The decrease in FH binding was associated with
a decrease in serum resistance for only some mutants (261-277 and 301-330). One
of these deletions affected the conformation of YadA (261-277), and this may
underlie the decrease in both FH binding and serum resistance. The other deletion
(301-330), however, was in a pentadecad register, and in addition, was partially
covered in those mutants whose ability to bind FH remained unaffected. This
observation suggests that a change of distance between the putative FH-binding
subsites on YadA, rather than deletion of the actual YadA site binding FH, results in a
reduction in FH binding.
Most serum-sensitive mutants did not lose their FH-binding ability (293-322, 308-
323, 323-363, 371-377). Moreover, the FH-binding mode of the mutants was
similar to that of the wild type YadA and involved SCRs of the entire polypeptide
193-218
 214-228
222-236 
231-246
244-258
247-262 
252-266
256-270
261-277
259-273
263-277
267-281
271-285
278-292
289-318
293-307
293-322
297-326
301-330
308-322
308-323
319-333
323-363
334-348
349-363
364-370
371-377
378-384
Figure 16. Schematic representation of deletions introduced to the stalk and neck regions of
YadA of Y. enterocolitica O:3 (IV).
RESULTS AND DISCUSSION
- 66 -  
chain of FH (Fig. 6 in IV). Although FH bound to YadA mutant proteins displayed
cofactor activity for FI-mediated cleavage of C3b (Fig. 5 in IV), one cannot ignore the
possibility that its ability to interfere with the formation of the alternative pathway
convertases or to accelerate their decay or both remained unaffected. In addition, the
excessive binding of FH by the mutants may result in FH depletion from serum and
thus trigger uncontrolled activation of the complement.
To conclude, FH does not target one particular segment of the YadA stalk. Instead, FH
binding to YadA appears to depend on the recognition of several complementing and
discontinuous structural YadA motifs. Moreover, the spacing of these motifs seems
crucial for the FH binding. The conformational and discontinuous nature of FH
binding has been reported for other proteins predicted to form coiled-coils,
streptococcal M protein, OspE and BBA68 of B. burgdorferi, and FhbA of B. hermsii
(Fischetti et al., 1995; Hovis et al., 2006; McDowell et al., 2004, 2005; Metts et al.,
2003). The structural motifs of these proteins were crucial for forming the binding site
for FH. Distortion of one of the three widely spaced coiled-coils of OspE resulted in
attenuated or completely abolished FH binding (McDowell et al., 2004; Metts et al.,
2003), whereas destabilization of the BBA68 coiled-coils resulted in reduced FH-
binding capacity (McDowell et al., 2005). Since none of the YadA deletions
completely abolished FH-binding ability, one could suggest that when one of the
YadA sites involved in the interaction is deleted, structural motifs elsewhere on the
right-handed part of the YadA stalk, having clear internal symmetry, may find
complementary regions on FH.
4.3.1.2 YadA and C4bp
Several proteins belonging to the family of trimeric autotransporters, such as H.
ducreyi DsrA, and M. catarrhalis UspA1 and UspA2, were shown to bind C4bp
(Abdullah et al., 2005; Nordström et al., 2004). Our receptor-mapping analysis pointed
to YadA as one of the C4bp receptors on Y. enterocolitica. We thus we wanted to
characterize YadA-C4bp interaction in more detail (V).
To show that the interaction between YadA and C4bp is direct, we tested the binding
of serum C4bp to TritonX-114-extracted YadA in affinity blotting. That we found
RESULTS AND DISCUSSION
- 67 -  
binding of C4bp to YadA trimer suggests a direct interaction between these proteins
(Fig. 6 in V).
To study whether the interaction between YadA and C4bp is ionic strength-dependent,
we examined the effect of salt on the YadA-C4bp interaction (Fig. 7 in V). Bacteria
expressing YadA were incubated with 125I-C4bp in the presence of salt (50-650 mM).
Because salt inhibits YadA-C4bp interaction at a concentration required to inhibit the
binding of C4bp to C4b (Blom et al., 2000), it is suggested that the positively charged
cluster of amino acids between CCP1 and CCP3, involved in C4b binding, would also
interact with YadA (Accardo et al., 1996; Härdig et al., 1997; Ogata et al., 1993).
Knowing that heparin competes with C4b for C4bp binding, by binding to CCP1-3
(Blom et al., 1999; Hessing et al., 1990; Villoutreix et al., 1998), we examined
whether it could inhibit C4bp-binding to YadA in an analogous fashion. Bacteria were
incubated with 125I-C4bp in the presence of heparin (0-1000 μg/ml), and its influence
on the binding was determined. Heparin weakly inhibited C4bp binding to YadA, and
a relatively high heparin concentration was required for 50% inhibition of the C4bp
binding to YadA (Fig. 7 in V). Although C4b/heparin and YadA do not appear to bind
to exactly the same site on C4bp, one cannot exclude the possibility that these binding
sites overlap.
We examined the functional activity of the YadA-bound C4bp by a cofactor assay. It
clearly showed that C4bp bound to YadA retained its regulatory function (Fig. 2 in V).
4.3.1.3 Ail and FH
Knowing that Ail contributed to FH binding when not blocked by LPS, we wanted to
study whether Ail-bound FH maintains its regulatory function. The cofactor assay
showed that Ail-bound FH was fully functional and displayed cofactor activity for FI-
mediated cleavage of C3b (Fig. 2 in III).
Next, we aimed to examine the nature of the interaction between Ail and FH. For that,
we incubated the single Ail-positive bacteria with purified FH in the presence of salt
(50-650 mM) or heparin (0-1000 μg/ml). That both salt and heparin reduced the FH
binding to Ail (Fig. 5 in III) suggests that the interaction between the proteins is ionic
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in nature and involves FH region(s) targeted by heparin, i. e. SCR 7, SCR 13, and SCR
20 (Blackmore et al., 1996, 1998b; Pangburn et al., 1991).
To map in more detail the FH regions involved in interaction with Ail, Ail-expressing
bacteria were incubated with the recombinant FH fragments that cover the whole FH
molecule. The results suggest that the SCR6 and SCR7 may constitute the binding site
for Ail (Fig. 17 and Fig. 4A in III).
4.3.1.3.1 Mapping Ail regions involved in FH binding
To identify the Ail region involved in binding of FH, we substituted amino acids
shown to be crucial for serotype O:8 Ail-mediated serum resistance (Miller et al.,
2001). We thus substituted single amino acids in loop 2 or loop 3, His65Ala and
Ser100Asp, respectively (IV, Fig. 18). Two mutants having double amino acid
substitutions in loop 2, Asp67Gly Leu68Gly and Asp67Ala Leu68Arg, expressed
minimal amounts of Ail and were not studied further (IV, Fig. 18).
Two single substitution mutants were tested for their ability to resist the complement-
mediated killing in the bactericidal assay. As the mutant bacteria showed decreased
resistance both to NHS and to EGTA-Mg serum, we wanted to examine whether their
Figure 18. Schematic representation of the amino acid substitutions introduced to Ail
of Y. enterocolitica serotype O:3, loops 1-4 (L1-4).
Figure 17. Schematic representation of FH domains interacting with Ail of Y. enterocolitica
serotype O:3
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ability to bind serum FH was affected by the mutations introduced. The mutants
displayed similar levels of bound FH as the wild type (Fig. 5 in IV). This suggested
that the Ail-mediated mechanism of serum resistance does not depend primarily on FH
binding. The biological significance of FH binding by Ail, a factor promoting Yersinia
entry into tissue culture cells in vitro (Miller and Falkow, 1988), could thus be related
to the attachment of bacteria to the glycosaminoglycans and sialic acids on host cells
via FH bridging.
4.3.1.4 Ail and C4bp
Knowing that Ail binds C4bp in the absence of LPS, we wanted to study whether that
the interaction between Ail and C4bp is direct. Binding of serum C4bp to -
octylglucoside- and TritonX-114-extracted Ail was tested in a ligand blotting assay.
No C4bp binding to Ail could be detected, however, suggesting that its conformational
structure is required for the binding to take place (V).
To characterize the Ail-C4bp binding in more detail we tested whether the binding is
dependent on charge (Fig. 7 in V). Bacteria expresssing Ail were incubated with 125I-
C4bp in the presence of heparin (0-1000 μg/ml) or salt (50-650 mM). Heparin
efficiently and dose-dependently inhibited the binding of C4bp to Ail, suggesting that
CCP1-3 domains of the C4bp -chain are involved. That the Ail-C4bp interaction was
less salt-sensitive than were YadA-C4bp or C4b-C4bp interactions (Blom et al., 2000)
indicates that the interaction is hydrophobic in nature. Thus, Ail binding sites on C4bp,
although apparently not equivalent, may still overlap with those involved in C4b- or
YadA- C4bp interactions.
To examine whether Ail-bound C4bp remained functionally active, the cofactor assay
was performed. The results clearly showed that C4bp bound to Ail-expressing bacteria
retained its regulatory function (Fig. 2 in V).
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5. CONCLUSIONS AND FUTURE PROSPECTS
In complement activation, FH and C4bp are the key regulators that prevent the
complement cascade from attacking host tissues. Some bacteria may bind and deposit
these regulators on their own surfaces and thus provide themselves with an efficient
means to avoid complement activation. In consequence, bacteria resist complement-
mediated lysis and opsonin-dependent phagocytosis.
This study has demonstrated that Y. enterocolitica, similar to many other pathogens,
recruits both FH and C4bp to its surface to ensure protection against the AP- and
CP/LP-mediated killing. YadA and Ail, the most crucial serum resistance factors of Y.
enterocolitica, mediate the binding of FH and C4bp. FH - YadA interaction involves
multiple higher structural motifs on the YadA stalk and the SCRs of the entire
polypeptide chain of FH. The Ail binding site on FH has been located to SCRs 6 and 7.
The binding site for FH on Ail, however, remains undetermined. Both YadA- and Ail-
bound regulators display full cofactor activity for FI-mediated cleavage of C3b/C4b.
FH/C4bp-binding characteristics do, however, differ between YadA and Ail. In
addition, Ail captures the regulators only in the absence of blocking O-ag and OC,
whereas YadA binds FH/C4bp independent of the presence of other surface factors.
Independent of mode of binding, however, YadA and Ail provide Y. enterocolitica a
means to avoid complement-mediated lysis, enhancing chances for the bacteria to
survive in the host during various phases of infection.
To investigate whether complement resistance contributes to pathogenesis of
yersiniosis in vivo would be of major importance. As YadA-mediated collagen binding
is essential for full virulence of Y. enterocolitica (Tamm et al., 1993), mice should be
challenged with serum-sensitive but collagen-binding Y. enterocolitica bacteria,
expressing YadA with the head and neck domains intact. In fact, Ackermann and co-
workers found that serum-sensitive Y. enterocolitica bacteria that express YadA
comprising the translocation unit of Oca family members showed attenuation in mice
(Ackermann et al., 2008). It thus appears that YadA-mediated serum resistance
contributes to bacterial virulence in vivo. It would be interesting, however, to examine
whether the correlation between serum sensitivity and virulence in the mouse model
could be observed also with the serum-sensitive YadA mutants generated in this study,
ones that carry the deletions within the stalk. It would also be of interest to show that
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the binding of FH/C4bp by Y. enterocolitica takes place in vivo. FH/C4bp-deficient
mice could serve to study how the lack of the regulators affects the pathogenesis of
yersiniosis.   
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